Duration (days)

Significant, Beneficial Change?

Dawczynski C, Massey KA, Ness C, Kiehntopf M, Stepanow S, Platzer M, Grün M, Nicolaou A, Jahreis G.

Clin Nutr. 2013 Oct;32(5):686-96. doi: 10.1016/j.clnu.2012.12.010. Epub 2012 Dec 28.

Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors.

"The observed increase of n-3 LC-PUFA in RBC and plasma lipids due to intake of n-3 LC-PUFA enriched yoghurt resulted in a reduction of cardiovascular risk factors and inflammatory mediators"

Dawczynski C, Massey KA, Ness C, Kiehntopf M, Stepanow S, Platzer M, Grün M, Nicolaou A, Jahreis G.

Clin Nutr. 2013 Oct;32(5):686-96. doi: 10.1016/j.clnu.2012.12.010. Epub 2012 Dec 28.

Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors.

"The observed increase of n-3 LC-PUFA in RBC and plasma lipids due to intake of n-3 LC-PUFA enriched yoghurt resulted in a reduction of cardiovascular risk factors and inflammatory mediators"

Dawczynski C, Massey KA, Ness C, Kiehntopf M, Stepanow S, Platzer M, Grün M, Nicolaou A, Jahreis G.

Clin Nutr. 2013 Oct;32(5):686-96. doi: 10.1016/j.clnu.2012.12.010. Epub 2012 Dec 28.

Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors.

"The observed increase of n-3 LC-PUFA in RBC and plasma lipids due to intake of n-3 LC-PUFA enriched yoghurt resulted in a reduction of cardiovascular risk factors and inflammatory mediators"

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

"IPE 4 g/day significantly reduced large VLDL, total LDL, small LDL, and total HDL particle concentrations and VLDL particle size in patients with TG ≥500 mg/dL"

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

"IPE 4 g/day significantly reduced large VLDL, total LDL, small LDL, and total HDL particle concentrations and VLDL particle size in patients with TG ≥500 mg/dL"

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

"IPE 4 g/day significantly reduced large VLDL, total LDL, small LDL, and total HDL particle concentrations and VLDL particle size in patients with TG ≥500 mg/dL"

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

"IPE 4 g/day significantly reduced large VLDL, total LDL, small LDL, and total HDL particle concentrations and VLDL particle size in patients with TG ≥500 mg/dL"

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

"IPE 4 g/day significantly reduced large VLDL, total LDL, small LDL, and total HDL particle concentrations and VLDL particle size in patients with TG ≥500 mg/dL"

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

"IPE 4 g/day significantly reduced large VLDL, total LDL, small LDL, and total HDL particle concentrations and VLDL particle size in patients with TG ≥500 mg/dL"

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

"IPE 4 g/day significantly reduced large VLDL, total LDL, small LDL, and total HDL particle concentrations and VLDL particle size in patients with TG ≥500 mg/dL"

Berger MM, Delodder F, Liaudet L, Tozzi P, Schlaepfer J, Chiolero RL, Tappy L.

Am J Clin Nutr. 2013 Feb;97(2):246-54. doi: 10.3945/ajcn.112.046573. Epub 2012 Dec 26.

Three short perioperative infusions of n-3 PUFAs reduce systemic inflammation induced by cardiopulmonary bypass surgery: a randomized controlled trial.

"These results suggest that perioperative FO may be beneficial in elective cardiac surgery with CPB."

Post-surgical core temperature

Berger MM, Delodder F, Liaudet L, Tozzi P, Schlaepfer J, Chiolero RL, Tappy L.

Am J Clin Nutr. 2013 Feb;97(2):246-54. doi: 10.3945/ajcn.112.046573. Epub 2012 Dec 26.

Three short perioperative infusions of n-3 PUFAs reduce systemic inflammation induced by cardiopulmonary bypass surgery: a randomized controlled trial.

"These results suggest that perioperative FO may be beneficial in elective cardiac surgery with CPB."

Berger MM, Delodder F, Liaudet L, Tozzi P, Schlaepfer J, Chiolero RL, Tappy L.

Am J Clin Nutr. 2013 Feb;97(2):246-54. doi: 10.3945/ajcn.112.046573. Epub 2012 Dec 26.

Three short perioperative infusions of n-3 PUFAs reduce systemic inflammation induced by cardiopulmonary bypass surgery: a randomized controlled trial.

"These results suggest that perioperative FO may be beneficial in elective cardiac surgery with CPB."

Berger MM, Delodder F, Liaudet L, Tozzi P, Schlaepfer J, Chiolero RL, Tappy L.

Am J Clin Nutr. 2013 Feb;97(2):246-54. doi: 10.3945/ajcn.112.046573. Epub 2012 Dec 26.

Three short perioperative infusions of n-3 PUFAs reduce systemic inflammation induced by cardiopulmonary bypass surgery: a randomized controlled trial.

"These results suggest that perioperative FO may be beneficial in elective cardiac surgery with CPB."

Berger MM, Delodder F, Liaudet L, Tozzi P, Schlaepfer J, Chiolero RL, Tappy L.

Am J Clin Nutr. 2013 Feb;97(2):246-54. doi: 10.3945/ajcn.112.046573. Epub 2012 Dec 26.

Three short perioperative infusions of n-3 PUFAs reduce systemic inflammation induced by cardiopulmonary bypass surgery: a randomized controlled trial.

"These results suggest that perioperative FO may be beneficial in elective cardiac surgery with CPB."

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators.

J Am Coll Cardiol. 2013 Jan 29;61(4):463-8. doi: 10.1016/j.jacc.2012.11.021. Epub 2012 Dec 19.

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.

"Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF"

Composite (Mortality, All-Cause, nonfatal stroke, nonfatal acute myocardial infarction (AMI), systemic embolism, heart failure development, or severe bleeding)

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators.

J Am Coll Cardiol. 2013 Jan 29;61(4):463-8. doi: 10.1016/j.jacc.2012.11.021. Epub 2012 Dec 19.

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.

"Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF"

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators.

J Am Coll Cardiol. 2013 Jan 29;61(4):463-8. doi: 10.1016/j.jacc.2012.11.021. Epub 2012 Dec 19.

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.

"Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF"

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators.

J Am Coll Cardiol. 2013 Jan 29;61(4):463-8. doi: 10.1016/j.jacc.2012.11.021. Epub 2012 Dec 19.

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.

"Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF"

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators.

J Am Coll Cardiol. 2013 Jan 29;61(4):463-8. doi: 10.1016/j.jacc.2012.11.021. Epub 2012 Dec 19.

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.

"Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF"

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators.

J Am Coll Cardiol. 2013 Jan 29;61(4):463-8. doi: 10.1016/j.jacc.2012.11.021. Epub 2012 Dec 19.

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.

"Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF"

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators.

J Am Coll Cardiol. 2013 Jan 29;61(4):463-8. doi: 10.1016/j.jacc.2012.11.021. Epub 2012 Dec 19.

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.

"Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF"

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators.

J Am Coll Cardiol. 2013 Jan 29;61(4):463-8. doi: 10.1016/j.jacc.2012.11.021. Epub 2012 Dec 19.

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.

"Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF"

Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, Ramos S, Tognoni G, Doval HC; GESICA Investigators.

J Am Coll Cardiol. 2013 Jan 29;61(4):463-8. doi: 10.1016/j.jacc.2012.11.021. Epub 2012 Dec 19.

Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.

"Pharmacological supplementation with 1 g of n-3 PUFA for 1 year did not reduce recurrent AF"

Iketani T, Takazawa K, Yamashina A.

Prostaglandins Leukot Essent Fatty Acids. 2013 Feb;88(2):191-5. doi: 10.1016/j.plefa.2012.11.008. Epub 2012 Dec 14.

"These results suggested that EPA but not pravastatin may reduce cardiac afterload by reducing vascular reflected waves and lowering C-SBP"

Blood Pressure, Systolic Central

Iketani T, Takazawa K, Yamashina A.

Prostaglandins Leukot Essent Fatty Acids. 2013 Feb;88(2):191-5. doi: 10.1016/j.plefa.2012.11.008. Epub 2012 Dec 14.

"These results suggested that EPA but not pravastatin may reduce cardiac afterload by reducing vascular reflected waves and lowering C-SBP"

Iketani T, Takazawa K, Yamashina A.

Prostaglandins Leukot Essent Fatty Acids. 2013 Feb;88(2):191-5. doi: 10.1016/j.plefa.2012.11.008. Epub 2012 Dec 14.

"These results suggested that EPA but not pravastatin may reduce cardiac afterload by reducing vascular reflected waves and lowering C-SBP"

Iketani T, Takazawa K, Yamashina A.

Prostaglandins Leukot Essent Fatty Acids. 2013 Feb;88(2):191-5. doi: 10.1016/j.plefa.2012.11.008. Epub 2012 Dec 14.

"These results suggested that EPA but not pravastatin may reduce cardiac afterload by reducing vascular reflected waves and lowering C-SBP"

Iketani T, Takazawa K, Yamashina A.

Prostaglandins Leukot Essent Fatty Acids. 2013 Feb;88(2):191-5. doi: 10.1016/j.plefa.2012.11.008. Epub 2012 Dec 14.

"These results suggested that EPA but not pravastatin may reduce cardiac afterload by reducing vascular reflected waves and lowering C-SBP"

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

NOS-derived superoxide production

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

McDonald DM, O'Kane F, McConville M, Devine AB, McVeigh GE.

Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.

Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids.

"Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT patients in vivo suggests a therapeutic role for these agents in reducing the vascular-derived oxidative stress associated with diabetes."

Logacheva IV, Barantseva NG, Vinokurova ES.

Kardiologiia. 2012;52(12):17-23. Russian.

[Influence of ω-3 PUFAs on predictors of sudden cardiac death in patients with Q-wave myocardial infarction].

"ω-3 PUFAs in patients with primary Q-wave MI was associated with decrease of ventricular ectopy severity in patients with low and high grade VHRD and simultaneous reduction of total myocardial ischemia time"

Logacheva IV, Barantseva NG, Vinokurova ES.

Kardiologiia. 2012;52(12):17-23. Russian.

[Influence of ω-3 PUFAs on predictors of sudden cardiac death in patients with Q-wave myocardial infarction].

"ω-3 PUFAs in patients with primary Q-wave MI was associated with decrease of ventricular ectopy severity in patients with low and high grade VHRD and simultaneous reduction of total myocardial ischemia time"

Logacheva IV, Barantseva NG, Vinokurova ES.

Kardiologiia. 2012;52(12):17-23. Russian.

[Influence of ω-3 PUFAs on predictors of sudden cardiac death in patients with Q-wave myocardial infarction].

"ω-3 PUFAs in patients with primary Q-wave MI was associated with decrease of ventricular ectopy severity in patients with low and high grade VHRD and simultaneous reduction of total myocardial ischemia time"

Logacheva IV, Barantseva NG, Vinokurova ES.

Kardiologiia. 2012;52(12):17-23. Russian.

[Influence of ω-3 PUFAs on predictors of sudden cardiac death in patients with Q-wave myocardial infarction].

"ω-3 PUFAs in patients with primary Q-wave MI was associated with decrease of ventricular ectopy severity in patients with low and high grade VHRD and simultaneous reduction of total myocardial ischemia time"

Logacheva IV, Barantseva NG, Vinokurova ES.

Kardiologiia. 2012;52(12):17-23. Russian.

[Influence of ω-3 PUFAs on predictors of sudden cardiac death in patients with Q-wave myocardial infarction].

"ω-3 PUFAs in patients with primary Q-wave MI was associated with decrease of ventricular ectopy severity in patients with low and high grade VHRD and simultaneous reduction of total myocardial ischemia time"

Microvolt-level T-Wave alternans

Din JN, Archer RM, Harding SA, Sarma J, Lyall K, Flapan AD, Newby DE.

Heart. 2013 Feb;99(3):168-74. doi: 10.1136/heartjnl-2012-302924. Epub 2012 Nov 26.

Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers.

"ω-3 fatty acids augment acute endothelial t-PA release and improve endothelial vasomotor function in cigarette smokers"

Endothelium-dependent vasodilatation with acetylcholine

Din JN, Archer RM, Harding SA, Sarma J, Lyall K, Flapan AD, Newby DE.

Heart. 2013 Feb;99(3):168-74. doi: 10.1136/heartjnl-2012-302924. Epub 2012 Nov 26.

Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers.

"ω-3 fatty acids augment acute endothelial t-PA release and improve endothelial vasomotor function in cigarette smokers"

Endothelium-dependent vasodilatation with substance P

Din JN, Archer RM, Harding SA, Sarma J, Lyall K, Flapan AD, Newby DE.

Heart. 2013 Feb;99(3):168-74. doi: 10.1136/heartjnl-2012-302924. Epub 2012 Nov 26.

Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers.

"ω-3 fatty acids augment acute endothelial t-PA release and improve endothelial vasomotor function in cigarette smokers"

Din JN, Archer RM, Harding SA, Sarma J, Lyall K, Flapan AD, Newby DE.

Heart. 2013 Feb;99(3):168-74. doi: 10.1136/heartjnl-2012-302924. Epub 2012 Nov 26.

Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers.

"ω-3 fatty acids augment acute endothelial t-PA release and improve endothelial vasomotor function in cigarette smokers"

platelet-monocyte aggregation

Din JN, Archer RM, Harding SA, Sarma J, Lyall K, Flapan AD, Newby DE.

Heart. 2013 Feb;99(3):168-74. doi: 10.1136/heartjnl-2012-302924. Epub 2012 Nov 26.

Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers.

"ω-3 fatty acids augment acute endothelial t-PA release and improve endothelial vasomotor function in cigarette smokers"

Din JN, Archer RM, Harding SA, Sarma J, Lyall K, Flapan AD, Newby DE.

Heart. 2013 Feb;99(3):168-74. doi: 10.1136/heartjnl-2012-302924. Epub 2012 Nov 26.

Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in male cigarette smokers.

"ω-3 fatty acids augment acute endothelial t-PA release and improve endothelial vasomotor function in cigarette smokers"

Vecka M, Dušejovská M, Stankova B, Zeman M, Vavrova L, Kodydkova J, Slaby A, Zak A.

Neuro Endocrinol Lett. 2012;33 Suppl 2:87-92.

N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.

"Our results support the opinion that hypertriacylglycerolemic patients benefit from the treatment with n-3 PUFA which improves several important metabolic factors of cardiovascular risk"

Vecka M, Dušejovská M, Stankova B, Zeman M, Vavrova L, Kodydkova J, Slaby A, Zak A.

Neuro Endocrinol Lett. 2012;33 Suppl 2:87-92.

N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.

"Our results support the opinion that hypertriacylglycerolemic patients benefit from the treatment with n-3 PUFA which improves several important metabolic factors of cardiovascular risk"

Vecka M, Dušejovská M, Stankova B, Zeman M, Vavrova L, Kodydkova J, Slaby A, Zak A.

Neuro Endocrinol Lett. 2012;33 Suppl 2:87-92.

N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.

"Our results support the opinion that hypertriacylglycerolemic patients benefit from the treatment with n-3 PUFA which improves several important metabolic factors of cardiovascular risk"

Vecka M, Dušejovská M, Stankova B, Zeman M, Vavrova L, Kodydkova J, Slaby A, Zak A.

Neuro Endocrinol Lett. 2012;33 Suppl 2:87-92.

N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.

"Our results support the opinion that hypertriacylglycerolemic patients benefit from the treatment with n-3 PUFA which improves several important metabolic factors of cardiovascular risk"

Vecka M, Dušejovská M, Stankova B, Zeman M, Vavrova L, Kodydkova J, Slaby A, Zak A.

Neuro Endocrinol Lett. 2012;33 Suppl 2:87-92.

N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.

"Our results support the opinion that hypertriacylglycerolemic patients benefit from the treatment with n-3 PUFA which improves several important metabolic factors of cardiovascular risk"

Vecka M, Dušejovská M, Stankova B, Zeman M, Vavrova L, Kodydkova J, Slaby A, Zak A.

Neuro Endocrinol Lett. 2012;33 Suppl 2:87-92.

N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.

"Our results support the opinion that hypertriacylglycerolemic patients benefit from the treatment with n-3 PUFA which improves several important metabolic factors of cardiovascular risk"

Nilsson A, Radeborg K, Salo I, Björck I.

Nutr J. 2012 Nov 22;11:99. doi: 10.1186/1475-2891-11-99.

Effects of supplementation with n-3 polyunsaturated fatty acids on cognitive performance and cardiometabolic risk markers in healthy 51 to 72 years old subjects: a randomized controlled cross-over study.

"Intake of n-3 PUFA improved cognitive performance in healthy subjects after five weeks compared with placebo. In addition, inverse relations were obtained between cardiometabolic risk factors and cognitive performance"

Nilsson A, Radeborg K, Salo I, Björck I.

Nutr J. 2012 Nov 22;11:99. doi: 10.1186/1475-2891-11-99.

Effects of supplementation with n-3 polyunsaturated fatty acids on cognitive performance and cardiometabolic risk markers in healthy 51 to 72 years old subjects: a randomized controlled cross-over study.

"Intake of n-3 PUFA improved cognitive performance in healthy subjects after five weeks compared with placebo. In addition, inverse relations were obtained between cardiometabolic risk factors and cognitive performance"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Hospitalization free from post-op AF

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Aterial thromboembolism, 30 days

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Aterial thromboembolism, >30 days

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G; OPERA Investigators.

JAMA. 2012 Nov 21;308(19):2001-11. Erratum in: JAMA. 2013 Mar 6;309(9):876.

Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.

"among patients undergoing cardiac surgery, peri-operative supplementation with n-3-PUFA, compared to placebo, did not reduce the risk of post-operative AF"

La Rovere MT, Staszewsky L, Barlera S, Maestri R, Mezzani A, Midi P, Marchioli R, Maggioni AP, Tognoni G, Tavazzi L, Latini R; GISSI-HF Investigators.

Heart Rhythm. 2013 Feb;10(2):226-32. doi: 10.1016/j.hrthm.2012.10.035. Epub 2012 Oct 26.

n-3PUFA and Holter-derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy.

"n-3PUFA supplementation partially restored autonomic modulation in patients with chronic HF"

La Rovere MT, Staszewsky L, Barlera S, Maestri R, Mezzani A, Midi P, Marchioli R, Maggioni AP, Tognoni G, Tavazzi L, Latini R; GISSI-HF Investigators.

Heart Rhythm. 2013 Feb;10(2):226-32. doi: 10.1016/j.hrthm.2012.10.035. Epub 2012 Oct 26.

n-3PUFA and Holter-derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy.

"n-3PUFA supplementation partially restored autonomic modulation in patients with chronic HF"

StDev of normal-to-normal RR Intervals

La Rovere MT, Staszewsky L, Barlera S, Maestri R, Mezzani A, Midi P, Marchioli R, Maggioni AP, Tognoni G, Tavazzi L, Latini R; GISSI-HF Investigators.

Heart Rhythm. 2013 Feb;10(2):226-32. doi: 10.1016/j.hrthm.2012.10.035. Epub 2012 Oct 26.

n-3PUFA and Holter-derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy.

"n-3PUFA supplementation partially restored autonomic modulation in patients with chronic HF"

La Rovere MT, Staszewsky L, Barlera S, Maestri R, Mezzani A, Midi P, Marchioli R, Maggioni AP, Tognoni G, Tavazzi L, Latini R; GISSI-HF Investigators.

Heart Rhythm. 2013 Feb;10(2):226-32. doi: 10.1016/j.hrthm.2012.10.035. Epub 2012 Oct 26.

n-3PUFA and Holter-derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy.

"n-3PUFA supplementation partially restored autonomic modulation in patients with chronic HF"

Yoneda H, Shirao S, Nakagawara J, Ogasawara K, Tominaga T, Suzuki M.

World Neurosurg. 2014 Feb;81(2):309-15. doi: 10.1016/j.wneu.2012.09.020. Epub 2012 Sep 29.

A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study.

"oral EPA reduces the frequency of SV and CIV after the onset of aneurysmal SAH"

Yoneda H, Shirao S, Nakagawara J, Ogasawara K, Tominaga T, Suzuki M.

World Neurosurg. 2014 Feb;81(2):309-15. doi: 10.1016/j.wneu.2012.09.020. Epub 2012 Sep 29.

A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study.

"oral EPA reduces the frequency of SV and CIV after the onset of aneurysmal SAH"

Schirmer SH, Werner CM, Binder SB, Faas ME, Custodis F, Böhm M, Laufs U.

Atherosclerosis. 2012 Nov;225(1):166-72. doi: 10.1016/j.atherosclerosis.2012.09.002. Epub 2012 Sep 13.

Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation.

"n3-FA reduce fasting TG and the postprandial TG increase"

Schirmer SH, Werner CM, Binder SB, Faas ME, Custodis F, Böhm M, Laufs U.

Atherosclerosis. 2012 Nov;225(1):166-72. doi: 10.1016/j.atherosclerosis.2012.09.002. Epub 2012 Sep 13.

Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation.

"n3-FA reduce fasting TG and the postprandial TG increase"

Schirmer SH, Werner CM, Binder SB, Faas ME, Custodis F, Böhm M, Laufs U.

Atherosclerosis. 2012 Nov;225(1):166-72. doi: 10.1016/j.atherosclerosis.2012.09.002. Epub 2012 Sep 13.

Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation.

"n3-FA reduce fasting TG and the postprandial TG increase"

Schirmer SH, Werner CM, Binder SB, Faas ME, Custodis F, Böhm M, Laufs U.

Atherosclerosis. 2012 Nov;225(1):166-72. doi: 10.1016/j.atherosclerosis.2012.09.002. Epub 2012 Sep 13.

Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation.

"n3-FA reduce fasting TG and the postprandial TG increase"

Ghorbanihaghjo A, Kolahi S, Seifirad S, Rashtchizadeh N, Argani H, Hajialilo M, Khabazi A, Alizadeh S, Bahreini E.

Arch Iran Med. 2012 Sep;15(9):549-52. doi: 012159/AIM.007.

Effect of fish oil supplements on serum paraoxonase activity in female patients with rheumatoid arthritis: a double-blind randomized controlled trial.

"FO could increase serum HDL-C and PON1 levels and Aryl activity in female patients with RA"

Ghorbanihaghjo A, Kolahi S, Seifirad S, Rashtchizadeh N, Argani H, Hajialilo M, Khabazi A, Alizadeh S, Bahreini E.

Arch Iran Med. 2012 Sep;15(9):549-52. doi: 012159/AIM.007.

Effect of fish oil supplements on serum paraoxonase activity in female patients with rheumatoid arthritis: a double-blind randomized controlled trial.

"FO could increase serum HDL-C and PON1 levels and Aryl activity in female patients with RA"

Ghorbanihaghjo A, Kolahi S, Seifirad S, Rashtchizadeh N, Argani H, Hajialilo M, Khabazi A, Alizadeh S, Bahreini E.

Arch Iran Med. 2012 Sep;15(9):549-52. doi: 012159/AIM.007.

Effect of fish oil supplements on serum paraoxonase activity in female patients with rheumatoid arthritis: a double-blind randomized controlled trial.

"FO could increase serum HDL-C and PON1 levels and Aryl activity in female patients with RA"

Ghorbanihaghjo A, Kolahi S, Seifirad S, Rashtchizadeh N, Argani H, Hajialilo M, Khabazi A, Alizadeh S, Bahreini E.

Arch Iran Med. 2012 Sep;15(9):549-52. doi: 012159/AIM.007.

Effect of fish oil supplements on serum paraoxonase activity in female patients with rheumatoid arthritis: a double-blind randomized controlled trial.

"FO could increase serum HDL-C and PON1 levels and Aryl activity in female patients with RA"

Ghorbanihaghjo A, Kolahi S, Seifirad S, Rashtchizadeh N, Argani H, Hajialilo M, Khabazi A, Alizadeh S, Bahreini E.

Arch Iran Med. 2012 Sep;15(9):549-52. doi: 012159/AIM.007.

Effect of fish oil supplements on serum paraoxonase activity in female patients with rheumatoid arthritis: a double-blind randomized controlled trial.

"FO could increase serum HDL-C and PON1 levels and Aryl activity in female patients with RA"

An WS, Lee SM, Son YK, Kim SE, Kim KH, Han JY, Bae HR, Rha SH, Park Y.

Nutr Res. 2012 Jul;32(7):495-502. doi: 10.1016/j.nutres.2012.06.005. Epub 2012 Jul 20.

Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients.

"omega-3 FA supplementation may have a clinical benefit caused by activating vitamin D, increasing fetuin-A levels...in dialysis patients"

An WS, Lee SM, Son YK, Kim SE, Kim KH, Han JY, Bae HR, Rha SH, Park Y.

Nutr Res. 2012 Jul;32(7):495-502. doi: 10.1016/j.nutres.2012.06.005. Epub 2012 Jul 20.

Omega-3 fatty acid supplementation increases 1,25-dihydroxyvitamin D and fetuin-A levels in dialysis patients.

"omega-3 FA supplementation may have a clinical benefit caused by activating vitamin D, increasing fetuin-A levels...in dialysis patients"

Gavva EM, Tsaregorodtsev DA, Mamedov IS, Sulimov VA.

Kardiologiia. 2012;52(7):14-21. Russian.

[Effect of ω-3 polyunsaturated fatty acids on predictors of sudden cardiac death in patients with ischemic heart disease and ventricular rhythm disturbances].

"6 months supplementation with 1 g/day ω-3 PUFA for 6 months in patients with IHD improves the effect of standard antiarrhythmic therapy, reducing the number of isolated and paired PVCs, the number of unstable ventricular tachycardia paroxysms, improves HRT, HRV, increases red blood cells ω-3 index"

Gavva EM, Tsaregorodtsev DA, Mamedov IS, Sulimov VA.

Kardiologiia. 2012;52(7):14-21. Russian.

[Effect of ω-3 polyunsaturated fatty acids on predictors of sudden cardiac death in patients with ischemic heart disease and ventricular rhythm disturbances].

"6 months supplementation with 1 g/day ω-3 PUFA for 6 months in patients with IHD improves the effect of standard antiarrhythmic therapy, reducing the number of isolated and paired PVCs, the number of unstable ventricular tachycardia paroxysms, improves HRT, HRV, increases red blood cells ω-3 index"

Gavva EM, Tsaregorodtsev DA, Mamedov IS, Sulimov VA.

Kardiologiia. 2012;52(7):14-21. Russian.

[Effect of ω-3 polyunsaturated fatty acids on predictors of sudden cardiac death in patients with ischemic heart disease and ventricular rhythm disturbances].

"6 months supplementation with 1 g/day ω-3 PUFA for 6 months in patients with IHD improves the effect of standard antiarrhythmic therapy, reducing the number of isolated and paired PVCs, the number of unstable ventricular tachycardia paroxysms, improves HRT, HRV, increases red blood cells ω-3 index"

Unstable ventricular tachycardia paroxysms

Gavva EM, Tsaregorodtsev DA, Mamedov IS, Sulimov VA.

Kardiologiia. 2012;52(7):14-21. Russian.

[Effect of ω-3 polyunsaturated fatty acids on predictors of sudden cardiac death in patients with ischemic heart disease and ventricular rhythm disturbances].

"6 months supplementation with 1 g/day ω-3 PUFA for 6 months in patients with IHD improves the effect of standard antiarrhythmic therapy, reducing the number of isolated and paired PVCs, the number of unstable ventricular tachycardia paroxysms, improves HRT, HRV, increases red blood cells ω-3 index"

Gavva EM, Tsaregorodtsev DA, Mamedov IS, Sulimov VA.

Kardiologiia. 2012;52(7):14-21. Russian.

[Effect of ω-3 polyunsaturated fatty acids on predictors of sudden cardiac death in patients with ischemic heart disease and ventricular rhythm disturbances].

"6 months supplementation with 1 g/day ω-3 PUFA for 6 months in patients with IHD improves the effect of standard antiarrhythmic therapy, reducing the number of isolated and paired PVCs, the number of unstable ventricular tachycardia paroxysms, improves HRT, HRV, increases red blood cells ω-3 index"

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

"AMR101 4 g/day significantly decreased median placebo-adjusted TG, non-HDL cholesterol, LDL cholesterol, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, lipoprotein-associated phospholipase A(2), and high-sensitivity hsCRP in statin-treated patients with residual TG elevations."

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

"AMR101 4 g/day significantly decreased median placebo-adjusted TG, non-HDL cholesterol, LDL cholesterol, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, lipoprotein-associated phospholipase A(2), and high-sensitivity hsCRP in statin-treated patients with residual TG elevations."

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

"AMR101 4 g/day significantly decreased median placebo-adjusted TG, non-HDL cholesterol, LDL cholesterol, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, lipoprotein-associated phospholipase A(2), and high-sensitivity hsCRP in statin-treated patients with residual TG elevations."

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

"AMR101 4 g/day significantly decreased median placebo-adjusted TG, non-HDL cholesterol, LDL cholesterol, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, lipoprotein-associated phospholipase A(2), and high-sensitivity hsCRP in statin-treated patients with residual TG elevations."

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

"AMR101 4 g/day significantly decreased median placebo-adjusted TG, non-HDL cholesterol, LDL cholesterol, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, lipoprotein-associated phospholipase A(2), and high-sensitivity hsCRP in statin-treated patients with residual TG elevations."

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

"AMR101 4 g/day significantly decreased median placebo-adjusted TG, non-HDL cholesterol, LDL cholesterol, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, lipoprotein-associated phospholipase A(2), and high-sensitivity hsCRP in statin-treated patients with residual TG elevations."

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

"AMR101 4 g/day significantly decreased median placebo-adjusted TG, non-HDL cholesterol, LDL cholesterol, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, lipoprotein-associated phospholipase A(2), and high-sensitivity hsCRP in statin-treated patients with residual TG elevations."

lipoprotein-associated phospholipase A(2)

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

"AMR101 4 g/day significantly decreased median placebo-adjusted TG, non-HDL cholesterol, LDL cholesterol, apolipoprotein B, total cholesterol, very-low-density lipoprotein cholesterol, lipoprotein-associated phospholipase A(2), and high-sensitivity hsCRP in statin-treated patients with residual TG elevations."

Carter JR, Schwartz CE, Yang H, Joyner MJ.

Am J Physiol Heart Circ Physiol. 2012 Aug 15;303(4):H450-6. doi: 10.1152/ajpheart.00353.2012. Epub 2012 Jun 15.

"our findings suggest that fish oil is associated with modest sympathoinhibition in individuals with higher resting heart rates, a finding that is consistent with a recent meta-analysis examining the relations among fish oil, HR, and the risk of cardiovascular disease."

Resting mean arterial pressure

Carter JR, Schwartz CE, Yang H, Joyner MJ.

Am J Physiol Heart Circ Physiol. 2012 Aug 15;303(4):H450-6. doi: 10.1152/ajpheart.00353.2012. Epub 2012 Jun 15.

"our findings suggest that fish oil is associated with modest sympathoinhibition in individuals with higher resting heart rates, a finding that is consistent with a recent meta-analysis examining the relations among fish oil, HR, and the risk of cardiovascular disease."

Muscle sympathetic nerve activity

Carter JR, Schwartz CE, Yang H, Joyner MJ.

Am J Physiol Heart Circ Physiol. 2012 Aug 15;303(4):H450-6. doi: 10.1152/ajpheart.00353.2012. Epub 2012 Jun 15.

"our findings suggest that fish oil is associated with modest sympathoinhibition in individuals with higher resting heart rates, a finding that is consistent with a recent meta-analysis examining the relations among fish oil, HR, and the risk of cardiovascular disease."

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

Hospitalization, Cardiovascular

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

"Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events"

Gajos G, Zalewski J, Nessler J, Zmudka K, Undas A, Piwowarska W.

Kardiol Pol. 2012;70(5):439-45.

Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.

"The addition of omega-3 ethyl esters significantly potentiates platelet response to clopidogrel after PCI mostly in patients with CYP2C19 loss-of-function polymorphism"

Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ.

Clin Nephrol. 2012 Jun;77(6):445-53.

The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.

"In patients with nephrotic range proteinuria, omega-3 fatty acids reduced triglyceride rich lipoproteins, LDL III and remnant lipoproteins"

Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ.

Clin Nephrol. 2012 Jun;77(6):445-53.

The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.

"In patients with nephrotic range proteinuria, omega-3 fatty acids reduced triglyceride rich lipoproteins, LDL III and remnant lipoproteins"

Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ.

Clin Nephrol. 2012 Jun;77(6):445-53.

The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.

"In patients with nephrotic range proteinuria, omega-3 fatty acids reduced triglyceride rich lipoproteins, LDL III and remnant lipoproteins"

Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ.

Clin Nephrol. 2012 Jun;77(6):445-53.

The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.

"In patients with nephrotic range proteinuria, omega-3 fatty acids reduced triglyceride rich lipoproteins, LDL III and remnant lipoproteins"

Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ.

Clin Nephrol. 2012 Jun;77(6):445-53.

The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.

"In patients with nephrotic range proteinuria, omega-3 fatty acids reduced triglyceride rich lipoproteins, LDL III and remnant lipoproteins"

Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ.

Clin Nephrol. 2012 Jun;77(6):445-53.

The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.

"In patients with nephrotic range proteinuria, omega-3 fatty acids reduced triglyceride rich lipoproteins, LDL III and remnant lipoproteins"

Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ.

Clin Nephrol. 2012 Jun;77(6):445-53.

The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.

"In patients with nephrotic range proteinuria, omega-3 fatty acids reduced triglyceride rich lipoproteins, LDL III and remnant lipoproteins"

Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ.

Clin Nephrol. 2012 Jun;77(6):445-53.

The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria.

"In patients with nephrotic range proteinuria, omega-3 fatty acids reduced triglyceride rich lipoproteins, LDL III and remnant lipoproteins"

Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, Oliver M, Donnelly S, Allon M, Stanley K; Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group.

JAMA. 2012 May 2;307(17):1809-16. doi: 10.1001/jama.2012.3473.

Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.

"Although fish oil improved some relevant secondary outcomes such as graft patency, rates of thrombosis, and interventions, other potential benefits on cardiovascular events require confirmation in future studies."

Grafts with native patency loss

Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, Oliver M, Donnelly S, Allon M, Stanley K; Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group.

JAMA. 2012 May 2;307(17):1809-16. doi: 10.1001/jama.2012.3473.

Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.

"Although fish oil improved some relevant secondary outcomes such as graft patency, rates of thrombosis, and interventions, other potential benefits on cardiovascular events require confirmation in future studies."

Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, Oliver M, Donnelly S, Allon M, Stanley K; Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group.

JAMA. 2012 May 2;307(17):1809-16. doi: 10.1001/jama.2012.3473.

Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.

"Although fish oil improved some relevant secondary outcomes such as graft patency, rates of thrombosis, and interventions, other potential benefits on cardiovascular events require confirmation in future studies."

Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, Oliver M, Donnelly S, Allon M, Stanley K; Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group.

JAMA. 2012 May 2;307(17):1809-16. doi: 10.1001/jama.2012.3473.

Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.

"Although fish oil improved some relevant secondary outcomes such as graft patency, rates of thrombosis, and interventions, other potential benefits on cardiovascular events require confirmation in future studies."

Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, Oliver M, Donnelly S, Allon M, Stanley K; Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group.

JAMA. 2012 May 2;307(17):1809-16. doi: 10.1001/jama.2012.3473.

Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.

"Although fish oil improved some relevant secondary outcomes such as graft patency, rates of thrombosis, and interventions, other potential benefits on cardiovascular events require confirmation in future studies."

Cardiovascular event-free survival

Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, Oliver M, Donnelly S, Allon M, Stanley K; Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group.

JAMA. 2012 May 2;307(17):1809-16. doi: 10.1001/jama.2012.3473.

Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.

"Although fish oil improved some relevant secondary outcomes such as graft patency, rates of thrombosis, and interventions, other potential benefits on cardiovascular events require confirmation in future studies."

Giltay EJ, Geleijnse JM, Heijboer AC, de Goede J, Oude Griep LM, Blankenstein MA, Kromhout D.

Int J Androl. 2012 Oct;35(5):680-7. doi: 10.1111/j.1365-2605.2012.01255.x. Epub 2012 Mar 6.

No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial.

"We conclude that n-3 fatty acids supplementation did not affect serum total testosterone in men who had had a MI."

Giltay EJ, Geleijnse JM, Heijboer AC, de Goede J, Oude Griep LM, Blankenstein MA, Kromhout D.

Int J Androl. 2012 Oct;35(5):680-7. doi: 10.1111/j.1365-2605.2012.01255.x. Epub 2012 Mar 6.

No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial.

"We conclude that n-3 fatty acids supplementation did not affect serum total testosterone in men who had had a MI."

Post-MI testosterone deficiency

Blacher J, Czernichow S, Paillard F, Ducimetiere P, Hercberg S, Galan P; SU.FOL.OM3 Study Research Group.

Int J Cardiol. 2013 Jul 31;167(2):508-13. doi: 10.1016/j.ijcard.2012.01.060. Epub 2012 Feb 23.

Cardiovascular effects of B-vitamins and/or N-3 fatty acids: the SU.FOL.OM3 trial.

"our results do not support the routine use of dietary supplements containing n-3 PUFA"

Blacher J, Czernichow S, Paillard F, Ducimetiere P, Hercberg S, Galan P; SU.FOL.OM3 Study Research Group.

Int J Cardiol. 2013 Jul 31;167(2):508-13. doi: 10.1016/j.ijcard.2012.01.060. Epub 2012 Feb 23.

Cardiovascular effects of B-vitamins and/or N-3 fatty acids: the SU.FOL.OM3 trial.

"our results do not support the routine use of dietary supplements containing n-3 PUFA"

Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ, Klungel OH, Kromhout D.

Eur Heart J. 2012 Jul;33(13):1582-8. doi: 10.1093/eurheartj/ehr499. Epub 2012 Feb 1.

Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction.

"In patients with a history of MI who are not treated with statins, low-dose supplementation with n-3 fatty acids may reduce major cardiovascular events"

Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J.

Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.

Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.

"Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease"

Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J.

Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.

Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.

"Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease"

Unstimulated P-selectin expression

Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J.

Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.

Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.

"Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease"

Stimulated P-selectin expression

Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J.

Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.

Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.

"Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease"

Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J.

Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.

Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.

"Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease"

Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J.

Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.

Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.

"Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease"

Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J.

Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.

Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.

"Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease"

Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J.

Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.

Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.

"Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease"

Mackay I, Ford I, Thies F, Fielding S, Bachoo P, Brittenden J.

Atherosclerosis. 2012 Apr;221(2):514-20. doi: 10.1016/j.atherosclerosis.2011.12.041. Epub 2012 Jan 13.

Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.

"Supplementation with Omega-3 fatty acids had no affect on platelet and endothelial activation or markers of inflammation in patients with peripheral arterial disease"

Sasaki J, Miwa T, Odawara M.

Endocr J. 2012;59(4):297-304. Epub 2012 Jan 27.

Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function.

"Our results showed that in patients with type 2 diabetes and receiving statin therapy whose LDL-C level was less than 100 mg/dL, the addition of highly purified EPA for 6 months significantly improved vascular function"

Duration of reactive hyperemia (DRH)

Sasaki J, Miwa T, Odawara M.

Endocr J. 2012;59(4):297-304. Epub 2012 Jan 27.

Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function.

"Our results showed that in patients with type 2 diabetes and receiving statin therapy whose LDL-C level was less than 100 mg/dL, the addition of highly purified EPA for 6 months significantly improved vascular function"

Sasaki J, Miwa T, Odawara M.

Endocr J. 2012;59(4):297-304. Epub 2012 Jan 27.

Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function.

"Our results showed that in patients with type 2 diabetes and receiving statin therapy whose LDL-C level was less than 100 mg/dL, the addition of highly purified EPA for 6 months significantly improved vascular function"

Sasaki J, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Itakura H, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators.

J Atheroscler Thromb. 2012;19(2):194-204. Epub 2011 Dec 17.

Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

"EPA was useful to reduce the occurrence of CAD in patients who did not achieve the goals for LDL-C and/or non-HDL-C."

Phang M, Lincz L, Seldon M, Garg ML.

J Nutr Biochem. 2012 Sep;23(9):1128-33. doi: 10.1016/j.jnutbio.2011.06.006. Epub 2011 Dec 1.

Acute supplementation with eicosapentaenoic acid reduces platelet microparticle activity in healthy subjects.

"EPA and DHA exert gender-dependent effects on platelet aggregation and platelet MP activity"

Phang M, Lincz L, Seldon M, Garg ML.

J Nutr Biochem. 2012 Sep;23(9):1128-33. doi: 10.1016/j.jnutbio.2011.06.006. Epub 2011 Dec 1.

Acute supplementation with eicosapentaenoic acid reduces platelet microparticle activity in healthy subjects.

"EPA and DHA exert gender-dependent effects on platelet aggregation and platelet MP activity"

Larsen BM, Goonewardene LA, Joffe AR, Van Aerde JE, Field CJ, Olstad DL, Clandinin MT.

Clin Nutr. 2012 Jun;31(3):322-9. doi: 10.1016/j.clnu.2011.11.006. Epub 2011 Dec 3.

Pre-treatment with an intravenous lipid emulsion containing fish oil (eicosapentaenoic and docosahexaenoic acid) decreases inflammatory markers after open-heart surgery in infants: a randomized, controlled trial.

"Providing a lipid emulsion containing eicosapentaenoic and docosahexaenoic acid reduces TNF-α concentrations in infants undergoing open-heart surgery"

Sorice M, Tritto FP, Sordelli C, Gregorio R, Piazza L.

Monaldi Arch Chest Dis. 2011 Jun;76(2):93-8.

N-3 polyunsaturated fatty acids reduces post-operative atrial fibrillation incidence in patients undergoing on-pump" coronary artery bypass graft surgery."

"N-3 polyunsaturated fatty acids administration significantly reduces the incidence of post-operative atrial fibrillation in patients undergoing "on-pump" coronary artery bypass graft surgery."

Sorice M, Tritto FP, Sordelli C, Gregorio R, Piazza L.

Monaldi Arch Chest Dis. 2011 Jun;76(2):93-8.

N-3 polyunsaturated fatty acids reduces post-operative atrial fibrillation incidence in patients undergoing on-pump" coronary artery bypass graft surgery."

"N-3 polyunsaturated fatty acids administration significantly reduces the incidence of post-operative atrial fibrillation in patients undergoing "on-pump" coronary artery bypass graft surgery."

Ginty AT, Conklin SM.

Biol Psychol. 2012 Jan;89(1):269-72. doi: 10.1016/j.biopsycho.2011.09.012. Epub 2011 Oct 1.

Preliminary evidence that acute long-chain omega-3 supplementation reduces cardiovascular reactivity to mental stress: a randomized and placebo controlled trial.

"Supplementation of omega-3 fatty acids may reduce cardiovascular reactivity to stress."

Gogolashvili NG, Litvinenko MV, Pochikaeva TN, Vavitova ES, Polikarpov LS, Novgorodtseva NIa.

Kardiologiia. 2011;51(8):28-31. Russian.

[Possibilities of a preparation omega-3 polyunsaturated fatty acids in the treatment of patients with ventricular arrhythmias and myocardial infarction].

"Administration of highly concentration preparation of omega-3 PUFAs for 3 months reduced number of PVCs per day, frequencies of grades 2, 3, 4A, 4B, and high grade PVCs (grades 3 - 5) as a whole."

Gogolashvili NG, Litvinenko MV, Pochikaeva TN, Vavitova ES, Polikarpov LS, Novgorodtseva NIa.

Kardiologiia. 2011;51(8):28-31. Russian.

[Possibilities of a preparation omega-3 polyunsaturated fatty acids in the treatment of patients with ventricular arrhythmias and myocardial infarction].

"Administration of highly concentration preparation of omega-3 PUFAs for 3 months reduced number of PVCs per day, frequencies of grades 2, 3, 4A, 4B, and high grade PVCs (grades 3 - 5) as a whole."

Gogolashvili NG, Litvinenko MV, Pochikaeva TN, Vavitova ES, Polikarpov LS, Novgorodtseva NIa.

Kardiologiia. 2011;51(8):28-31. Russian.

[Possibilities of a preparation omega-3 polyunsaturated fatty acids in the treatment of patients with ventricular arrhythmias and myocardial infarction].

"Administration of highly concentration preparation of omega-3 PUFAs for 3 months reduced number of PVCs per day, frequencies of grades 2, 3, 4A, 4B, and high grade PVCs (grades 3 - 5) as a whole."

Gogolashvili NG, Litvinenko MV, Pochikaeva TN, Vavitova ES, Polikarpov LS, Novgorodtseva NIa.

Kardiologiia. 2011;51(8):28-31. Russian.

[Possibilities of a preparation omega-3 polyunsaturated fatty acids in the treatment of patients with ventricular arrhythmias and myocardial infarction].

"Administration of highly concentration preparation of omega-3 PUFAs for 3 months reduced number of PVCs per day, frequencies of grades 2, 3, 4A, 4B, and high grade PVCs (grades 3 - 5) as a whole."

Gogolashvili NG, Litvinenko MV, Pochikaeva TN, Vavitova ES, Polikarpov LS, Novgorodtseva NIa.

Kardiologiia. 2011;51(8):28-31. Russian.

[Possibilities of a preparation omega-3 polyunsaturated fatty acids in the treatment of patients with ventricular arrhythmias and myocardial infarction].

"Administration of highly concentration preparation of omega-3 PUFAs for 3 months reduced number of PVCs per day, frequencies of grades 2, 3, 4A, 4B, and high grade PVCs (grades 3 - 5) as a whole."

Gogolashvili NG, Litvinenko MV, Pochikaeva TN, Vavitova ES, Polikarpov LS, Novgorodtseva NIa.

Kardiologiia. 2011;51(8):28-31. Russian.

[Possibilities of a preparation omega-3 polyunsaturated fatty acids in the treatment of patients with ventricular arrhythmias and myocardial infarction].

"Administration of highly concentration preparation of omega-3 PUFAs for 3 months reduced number of PVCs per day, frequencies of grades 2, 3, 4A, 4B, and high grade PVCs (grades 3 - 5) as a whole."

Kirkhus B, Lamglait A, Eilertsen KE, Falch E, Haider T, Vik H, Hoem N, Hagve TA, Basu S, Olsen E, Seljeflot I, Nyberg L, Elind E, Ulven SM.

Br J Nutr. 2012 May;107(9):1339-49. doi: 10.1017/S0007114511004508. Epub 2011 Sep 15.

Effects of similar intakes of marine n-3 fatty acids from enriched food products and fish oil on cardiovascular risk markers in healthy human subjects.

"although the dose given is known to reduce the risk of CVD, no significant changes were observed on cardiovascular risk markers in this healthy population"

Hileman CO, Carman TL, Storer NJ, Labbato DE, White CA, McComsey GA.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):649-55. doi: 10.1089/AID.2011.0088. Epub 2011 Oct 17.

"omega-3 fatty acids may not be potent enough to counteract the enhanced inflammation and endothelial dysfunction due to HIV and antiretrovirals."

Hileman CO, Carman TL, Storer NJ, Labbato DE, White CA, McComsey GA.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):649-55. doi: 10.1089/AID.2011.0088. Epub 2011 Oct 17.

"omega-3 fatty acids may not be potent enough to counteract the enhanced inflammation and endothelial dysfunction due to HIV and antiretrovirals."

Hileman CO, Carman TL, Storer NJ, Labbato DE, White CA, McComsey GA.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):649-55. doi: 10.1089/AID.2011.0088. Epub 2011 Oct 17.

"omega-3 fatty acids may not be potent enough to counteract the enhanced inflammation and endothelial dysfunction due to HIV and antiretrovirals."

Hileman CO, Carman TL, Storer NJ, Labbato DE, White CA, McComsey GA.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):649-55. doi: 10.1089/AID.2011.0088. Epub 2011 Oct 17.

"omega-3 fatty acids may not be potent enough to counteract the enhanced inflammation and endothelial dysfunction due to HIV and antiretrovirals."

Hileman CO, Carman TL, Storer NJ, Labbato DE, White CA, McComsey GA.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):649-55. doi: 10.1089/AID.2011.0088. Epub 2011 Oct 17.

"omega-3 fatty acids may not be potent enough to counteract the enhanced inflammation and endothelial dysfunction due to HIV and antiretrovirals."

Hileman CO, Carman TL, Storer NJ, Labbato DE, White CA, McComsey GA.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):649-55. doi: 10.1089/AID.2011.0088. Epub 2011 Oct 17.

"omega-3 fatty acids may not be potent enough to counteract the enhanced inflammation and endothelial dysfunction due to HIV and antiretrovirals."

Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienczyk PJ.

Am J Clin Nutr. 2011 Oct;94(4):973-80. doi: 10.3945/ajcn.111.018036. Epub 2011 Aug 24.

Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial.

"Intakes of n-3 LC-PUFAs ≤1.8 g/d do not improve endothelial function in healthy adults"

Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienczyk PJ.

Am J Clin Nutr. 2011 Oct;94(4):973-80. doi: 10.3945/ajcn.111.018036. Epub 2011 Aug 24.

Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial.

"Intakes of n-3 LC-PUFAs ≤1.8 g/d do not improve endothelial function in healthy adults"

Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienczyk PJ.

Am J Clin Nutr. 2011 Oct;94(4):973-80. doi: 10.3945/ajcn.111.018036. Epub 2011 Aug 24.

Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial.

"Intakes of n-3 LC-PUFAs ≤1.8 g/d do not improve endothelial function in healthy adults"

Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienczyk PJ.

Am J Clin Nutr. 2011 Oct;94(4):973-80. doi: 10.3945/ajcn.111.018036. Epub 2011 Aug 24.

Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial.

"Intakes of n-3 LC-PUFAs ≤1.8 g/d do not improve endothelial function in healthy adults"

Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienczyk PJ.

Am J Clin Nutr. 2011 Oct;94(4):973-80. doi: 10.3945/ajcn.111.018036. Epub 2011 Aug 24.

Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial.

"Intakes of n-3 LC-PUFAs ≤1.8 g/d do not improve endothelial function in healthy adults"

Blood Pressure, 24h Ambulatory

Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L.

Circulation. 2011 Sep 6;124(10):1100-6. doi: 10.1161/CIRCULATIONAHA.111.022194. Epub 2011 Aug 15.

n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study.

"Our data suggest that n-3 PUFAs may exert beneficial effects in the prevention of atrial fibrillation recurrence."

Paniagua JA, Pérez-Martinez P, Gjelstad IM, Tierney AC, Delgado-Lista J, Defoort C, Blaak EE, Risérus U, Drevon CA, Kiec-Wilk B, Lovegrove JA, Roche HM, López-Miranda J; LIPGENE Study Investigators.

Atherosclerosis. 2011 Oct;218(2):443-50. doi: 10.1016/j.atherosclerosis.2011.07.003. Epub 2011 Jul 12.

A low-fat high-carbohydrate diet supplemented with long-chain n-3 PUFA reduces the risk of the metabolic syndrome.

"The consumption of a low-fat high-carbohydrate supplemented with n-3 diet reduced the risk of MetS as compared with isoenergetic high-fat (HSFA and HMUFA) and LFHCC diets."

Paniagua JA, Pérez-Martinez P, Gjelstad IM, Tierney AC, Delgado-Lista J, Defoort C, Blaak EE, Risérus U, Drevon CA, Kiec-Wilk B, Lovegrove JA, Roche HM, López-Miranda J; LIPGENE Study Investigators.

Atherosclerosis. 2011 Oct;218(2):443-50. doi: 10.1016/j.atherosclerosis.2011.07.003. Epub 2011 Jul 12.

A low-fat high-carbohydrate diet supplemented with long-chain n-3 PUFA reduces the risk of the metabolic syndrome.

"The consumption of a low-fat high-carbohydrate supplemented with n-3 diet reduced the risk of MetS as compared with isoenergetic high-fat (HSFA and HMUFA) and LFHCC diets."

Newens KJ, Thompson AK, Jackson KG, Wright J, Williams CM.

Am J Clin Nutr. 2011 Sep;94(3):742-8. doi: 10.3945/ajcn.110.009233. Epub 2011 Aug 10.

DHA-rich fish oil reverses the detrimental effects of saturated fatty acids on postprandial vascular reactivity.

"The beneficial effect of LC n-3 PUFAs on postprandial vascular function warrants further investigation but may be mediated by nitric oxide-independent mechanisms."

Newens KJ, Thompson AK, Jackson KG, Wright J, Williams CM.

Am J Clin Nutr. 2011 Sep;94(3):742-8. doi: 10.3945/ajcn.110.009233. Epub 2011 Aug 10.

DHA-rich fish oil reverses the detrimental effects of saturated fatty acids on postprandial vascular reactivity.

"The beneficial effect of LC n-3 PUFAs on postprandial vascular function warrants further investigation but may be mediated by nitric oxide-independent mechanisms."

laser Doppler iontophoresis (LDI)

Newens KJ, Thompson AK, Jackson KG, Wright J, Williams CM.

Am J Clin Nutr. 2011 Sep;94(3):742-8. doi: 10.3945/ajcn.110.009233. Epub 2011 Aug 10.

DHA-rich fish oil reverses the detrimental effects of saturated fatty acids on postprandial vascular reactivity.

"The beneficial effect of LC n-3 PUFAs on postprandial vascular function warrants further investigation but may be mediated by nitric oxide-independent mechanisms."

Szabo de Edelenyi F, Vergnaud AC, Ahluwalia N, Julia C, Hercberg S, Blacher J, Galan P.

Br J Nutr. 2012 Mar;107(6):921-7. doi: 10.1017/S0007114511003692. Epub 2011 Aug 1.

Effect of B-vitamins and n-3 PUFA supplementation for 5 years on blood pressure in patients with CVD.

"the present results do not support the routine use of dietary supplements containing B-vitamins, or of n-3 fatty acids, to reduce BP in people with prior CVD."

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Monocyte-platelet aggregates

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Monocyte chemotactic protein-1

Moertl D, Berger R, Hammer A, Hutuleac R, Koppensteiner R, Kopp CW, Steiner S.

Thromb Haemost. 2011 Sep;106(3):457-65. doi: 10.1160/TH-11-03-0169. Epub 2011 Jul 28.

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure.

"In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF."

Kirkegaard E, Svensson M, Strandhave C, Schmidt EB, Jørgensen KA, Christensen JH.

Br J Nutr. 2012 Mar;107(6):903-9. doi: 10.1017/S0007114511003771. Epub 2011 Jul 26.

Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.

"Intervention with n-3 PUFA did not shorten the QTc interval compared to placebo."

Kirkegaard E, Svensson M, Strandhave C, Schmidt EB, Jørgensen KA, Christensen JH.

Br J Nutr. 2012 Mar;107(6):903-9. doi: 10.1017/S0007114511003771. Epub 2011 Jul 26.

Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.

"Intervention with n-3 PUFA did not shorten the QTc interval compared to placebo."

Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA, Cleland LG, Sullivan TR, James MJ, Young GD.

Am J Cardiol. 2011 Sep 15;108(6):851-6. doi: 10.1016/j.amjcard.2011.04.036. Epub 2011 Jul 15.

"supplementation with dietary fish oil did not result in a significant decrease in the incidence of postsurgical AF. However, there was a significant decrease in time spent in the intensive care unit."

Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA, Cleland LG, Sullivan TR, James MJ, Young GD.

Am J Cardiol. 2011 Sep 15;108(6):851-6. doi: 10.1016/j.amjcard.2011.04.036. Epub 2011 Jul 15.

"supplementation with dietary fish oil did not result in a significant decrease in the incidence of postsurgical AF. However, there was a significant decrease in time spent in the intensive care unit."

Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA, Cleland LG, Sullivan TR, James MJ, Young GD.

Am J Cardiol. 2011 Sep 15;108(6):851-6. doi: 10.1016/j.amjcard.2011.04.036. Epub 2011 Jul 15.

"supplementation with dietary fish oil did not result in a significant decrease in the incidence of postsurgical AF. However, there was a significant decrease in time spent in the intensive care unit."

Kooshki A, Taleban FA, Tabibi H, Hedayati M.

Ann Nutr Metab. 2011;58(3):197-202. doi: 10.1159/000329727. Epub 2011 Jul 9.

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.

"The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases"

Soluble Intercellular Adhesion Molecule-1 (sICAM-1)

Kooshki A, Taleban FA, Tabibi H, Hedayati M.

Ann Nutr Metab. 2011;58(3):197-202. doi: 10.1159/000329727. Epub 2011 Jul 9.

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.

"The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases"

Soluble Vascular Adhesion Molecule-1 (sVCAM-1)

Kooshki A, Taleban FA, Tabibi H, Hedayati M.

Ann Nutr Metab. 2011;58(3):197-202. doi: 10.1159/000329727. Epub 2011 Jul 9.

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.

"The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases"

Kooshki A, Taleban FA, Tabibi H, Hedayati M.

Ann Nutr Metab. 2011;58(3):197-202. doi: 10.1159/000329727. Epub 2011 Jul 9.

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.

"The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases"

Kooshki A, Taleban FA, Tabibi H, Hedayati M.

Ann Nutr Metab. 2011;58(3):197-202. doi: 10.1159/000329727. Epub 2011 Jul 9.

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.

"The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases"

Kooshki A, Taleban FA, Tabibi H, Hedayati M.

Ann Nutr Metab. 2011;58(3):197-202. doi: 10.1159/000329727. Epub 2011 Jul 9.

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.

"The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases"

Kooshki A, Taleban FA, Tabibi H, Hedayati M.

Ann Nutr Metab. 2011;58(3):197-202. doi: 10.1159/000329727. Epub 2011 Jul 9.

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.

"The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases"

Kooshki A, Taleban FA, Tabibi H, Hedayati M.

Ann Nutr Metab. 2011;58(3):197-202. doi: 10.1159/000329727. Epub 2011 Jul 9.

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.

"The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases"

Kooshki A, Taleban FA, Tabibi H, Hedayati M.

Ann Nutr Metab. 2011;58(3):197-202. doi: 10.1159/000329727. Epub 2011 Jul 9.

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.

"The results of the present study indicate that marine omega-3 fatty acids can reduce serum sICAM-1, a risk factor for cardiovascular diseases"

García-Alonso FJ, Jorge-Vidal V, Ros G, Periago MJ.

Eur J Nutr. 2012 Jun;51(4):415-24. doi: 10.1007/s00394-011-0225-0. Epub 2011 Jul 14.

Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women.

"Overall, stronger positive amelioration of CVD risk factors was observed following the intake of n-3 PUFA-enriched juice than after plain tomato juice consumption"

García-Alonso FJ, Jorge-Vidal V, Ros G, Periago MJ.

Eur J Nutr. 2012 Jun;51(4):415-24. doi: 10.1007/s00394-011-0225-0. Epub 2011 Jul 14.

Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women.

"Overall, stronger positive amelioration of CVD risk factors was observed following the intake of n-3 PUFA-enriched juice than after plain tomato juice consumption"

García-Alonso FJ, Jorge-Vidal V, Ros G, Periago MJ.

Eur J Nutr. 2012 Jun;51(4):415-24. doi: 10.1007/s00394-011-0225-0. Epub 2011 Jul 14.

Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women.

"Overall, stronger positive amelioration of CVD risk factors was observed following the intake of n-3 PUFA-enriched juice than after plain tomato juice consumption"

García-Alonso FJ, Jorge-Vidal V, Ros G, Periago MJ.

Eur J Nutr. 2012 Jun;51(4):415-24. doi: 10.1007/s00394-011-0225-0. Epub 2011 Jul 14.

Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women.

"Overall, stronger positive amelioration of CVD risk factors was observed following the intake of n-3 PUFA-enriched juice than after plain tomato juice consumption"

García-Alonso FJ, Jorge-Vidal V, Ros G, Periago MJ.

Eur J Nutr. 2012 Jun;51(4):415-24. doi: 10.1007/s00394-011-0225-0. Epub 2011 Jul 14.

Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women.

"Overall, stronger positive amelioration of CVD risk factors was observed following the intake of n-3 PUFA-enriched juice than after plain tomato juice consumption"

García-Alonso FJ, Jorge-Vidal V, Ros G, Periago MJ.

Eur J Nutr. 2012 Jun;51(4):415-24. doi: 10.1007/s00394-011-0225-0. Epub 2011 Jul 14.

Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women.

"Overall, stronger positive amelioration of CVD risk factors was observed following the intake of n-3 PUFA-enriched juice than after plain tomato juice consumption"

Soluble Vascular Adhesion Molecule-1 (sVCAM-1)

García-Alonso FJ, Jorge-Vidal V, Ros G, Periago MJ.

Eur J Nutr. 2012 Jun;51(4):415-24. doi: 10.1007/s00394-011-0225-0. Epub 2011 Jul 14.

Effect of consumption of tomato juice enriched with n-3 polyunsaturated fatty acids on the lipid profile, antioxidant biomarker status, and cardiovascular disease risk in healthy women.

"Overall, stronger positive amelioration of CVD risk factors was observed following the intake of n-3 PUFA-enriched juice than after plain tomato juice consumption"

Soluble Intercellular Adhesion Molecule-1 (sICAM-1)

Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D.

Cardiology. 2011;118(3):187-94. doi: 10.1159/000329300. Epub 2011 Jun 22.

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.

"Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers"

Platelet aggregation, ADP-induced

Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D.

Cardiology. 2011;118(3):187-94. doi: 10.1159/000329300. Epub 2011 Jun 22.

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.

"Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers"

Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D.

Cardiology. 2011;118(3):187-94. doi: 10.1159/000329300. Epub 2011 Jun 22.

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.

"Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers"

Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D.

Cardiology. 2011;118(3):187-94. doi: 10.1159/000329300. Epub 2011 Jun 22.

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.

"Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers"

Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D.

Cardiology. 2011;118(3):187-94. doi: 10.1159/000329300. Epub 2011 Jun 22.

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.

"Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers"

platelet/endothelial cell adhesion molecule

Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D.

Cardiology. 2011;118(3):187-94. doi: 10.1159/000329300. Epub 2011 Jun 22.

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.

"Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers"

Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D.

Cardiology. 2011;118(3):187-94. doi: 10.1159/000329300. Epub 2011 Jun 22.

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.

"Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers"

formation of platelet-monocyte microparticles

Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D.

Cardiology. 2011;118(3):187-94. doi: 10.1159/000329300. Epub 2011 Jun 22.

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.

"Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers"

Takaki A, Umemoto S, Ono K, Seki K, Ryoke T, Fujii A, Itagaki T, Harada M, Tanaka M, Yonezawa T, Ogawa H, Matsuzaki M; ELIA study group.

J Atheroscler Thromb. 2011;18(10):857-66. Epub 2011 Jun 23.

Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study.

"EPA may reduce oxidative stress and inhibit the progression of arterial stiffness more efficiently than statin-only therapy in patients with dyslipidemia and CAD"

Pulse Wave Velocity, brachial-ankle (baPWV)

Takaki A, Umemoto S, Ono K, Seki K, Ryoke T, Fujii A, Itagaki T, Harada M, Tanaka M, Yonezawa T, Ogawa H, Matsuzaki M; ELIA study group.

J Atheroscler Thromb. 2011;18(10):857-66. Epub 2011 Jun 23.

Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study.

"EPA may reduce oxidative stress and inhibit the progression of arterial stiffness more efficiently than statin-only therapy in patients with dyslipidemia and CAD"

Takaki A, Umemoto S, Ono K, Seki K, Ryoke T, Fujii A, Itagaki T, Harada M, Tanaka M, Yonezawa T, Ogawa H, Matsuzaki M; ELIA study group.

J Atheroscler Thromb. 2011;18(10):857-66. Epub 2011 Jun 23.

Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study.

"EPA may reduce oxidative stress and inhibit the progression of arterial stiffness more efficiently than statin-only therapy in patients with dyslipidemia and CAD"

Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1696-702. doi: 10.1161/ATVBAHA.111.228593. Epub 2011 May 26.

Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).

"Adding n-3 PUFA to standard therapy in stable patients undergoing PCI significantly decreases thrombin formation and oxidative stress and favorably alters fibrin clot properties"

Plasma fibrin clot permeability (K(s))

Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1696-702. doi: 10.1161/ATVBAHA.111.228593. Epub 2011 May 26.

Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).

"Adding n-3 PUFA to standard therapy in stable patients undergoing PCI significantly decreases thrombin formation and oxidative stress and favorably alters fibrin clot properties"

Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1696-702. doi: 10.1161/ATVBAHA.111.228593. Epub 2011 May 26.

Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).

"Adding n-3 PUFA to standard therapy in stable patients undergoing PCI significantly decreases thrombin formation and oxidative stress and favorably alters fibrin clot properties"

Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1696-702. doi: 10.1161/ATVBAHA.111.228593. Epub 2011 May 26.

Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).

"Adding n-3 PUFA to standard therapy in stable patients undergoing PCI significantly decreases thrombin formation and oxidative stress and favorably alters fibrin clot properties"

Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1696-702. doi: 10.1161/ATVBAHA.111.228593. Epub 2011 May 26.

Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).

"Adding n-3 PUFA to standard therapy in stable patients undergoing PCI significantly decreases thrombin formation and oxidative stress and favorably alters fibrin clot properties"

Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1696-702. doi: 10.1161/ATVBAHA.111.228593. Epub 2011 May 26.

Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).

"Adding n-3 PUFA to standard therapy in stable patients undergoing PCI significantly decreases thrombin formation and oxidative stress and favorably alters fibrin clot properties"

8-isoprostaglandin F(2α) (8-iso-PGF(2α)

Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1696-702. doi: 10.1161/ATVBAHA.111.228593. Epub 2011 May 26.

Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).

"Adding n-3 PUFA to standard therapy in stable patients undergoing PCI significantly decreases thrombin formation and oxidative stress and favorably alters fibrin clot properties"

Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A.

Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1696-702. doi: 10.1161/ATVBAHA.111.228593. Epub 2011 May 26.

Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot).

"Adding n-3 PUFA to standard therapy in stable patients undergoing PCI significantly decreases thrombin formation and oxidative stress and favorably alters fibrin clot properties"

Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R.

Am Heart J. 2011 May;161(5):915.e1-9. doi: 10.1016/j.ahj.2011.02.011.

Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study.

"Treatment with n3-PUFA for 3 months exerts a dose-dependent increase of LVEF in patients with CHF. In parallel, a significant improvement of endothelial function and decrease of interleukin 6 is found with high-dose n3-PUFA intervention."

Left ventricular ejection fraction

Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R.

Am Heart J. 2011 May;161(5):915.e1-9. doi: 10.1016/j.ahj.2011.02.011.

Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study.

"Treatment with n3-PUFA for 3 months exerts a dose-dependent increase of LVEF in patients with CHF. In parallel, a significant improvement of endothelial function and decrease of interleukin 6 is found with high-dose n3-PUFA intervention."

Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R.

Am Heart J. 2011 May;161(5):915.e1-9. doi: 10.1016/j.ahj.2011.02.011.

Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study.

"Treatment with n3-PUFA for 3 months exerts a dose-dependent increase of LVEF in patients with CHF. In parallel, a significant improvement of endothelial function and decrease of interleukin 6 is found with high-dose n3-PUFA intervention."

Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R.

Am Heart J. 2011 May;161(5):915.e1-9. doi: 10.1016/j.ahj.2011.02.011.

Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study.

"Treatment with n3-PUFA for 3 months exerts a dose-dependent increase of LVEF in patients with CHF. In parallel, a significant improvement of endothelial function and decrease of interleukin 6 is found with high-dose n3-PUFA intervention."

Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R.

Am Heart J. 2011 May;161(5):915.e1-9. doi: 10.1016/j.ahj.2011.02.011.

Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study.

"Treatment with n3-PUFA for 3 months exerts a dose-dependent increase of LVEF in patients with CHF. In parallel, a significant improvement of endothelial function and decrease of interleukin 6 is found with high-dose n3-PUFA intervention."

Bragt MC, Mensink RP.

Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):966-73. doi: 10.1016/j.numecd.2010.12.010. Epub 2011 Mar 22.

Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.

"Although n-3 LCPUFA and fenofibrate can both activate PPARα, they have differential effects on cardiovascular risk markers."

Bragt MC, Mensink RP.

Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):966-73. doi: 10.1016/j.numecd.2010.12.010. Epub 2011 Mar 22.

Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.

"Although n-3 LCPUFA and fenofibrate can both activate PPARα, they have differential effects on cardiovascular risk markers."

Bragt MC, Mensink RP.

Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):966-73. doi: 10.1016/j.numecd.2010.12.010. Epub 2011 Mar 22.

Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.

"Although n-3 LCPUFA and fenofibrate can both activate PPARα, they have differential effects on cardiovascular risk markers."

Bragt MC, Mensink RP.

Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):966-73. doi: 10.1016/j.numecd.2010.12.010. Epub 2011 Mar 22.

Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.

"Although n-3 LCPUFA and fenofibrate can both activate PPARα, they have differential effects on cardiovascular risk markers."

Bragt MC, Mensink RP.

Nutr Metab Cardiovasc Dis. 2012 Nov;22(11):966-73. doi: 10.1016/j.numecd.2010.12.010. Epub 2011 Mar 22.

Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.

"Although n-3 LCPUFA and fenofibrate can both activate PPARα, they have differential effects on cardiovascular risk markers."

Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A, Mezzani A, Favero C, Franzosi MG, Serra D, Lucci D, Bianchini F, Bernasconi R, Maggioni AP, Nicolosi G, Porcu M, Tognoni G, Tavazzi L, Marchioli R.

Am Heart J. 2011 Feb;161(2):338-343.e1. doi: 10.1016/j.ahj.2010.10.032.

Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial.

"The results of this study, though not statistically significant, support prior evidences of an antiarrhythmic effect of n-3PUFA in patients with ICD"

Kumar S, Sutherland F, Wheeler M, Heck PM, Lee G, Teh AW, Garg ML, Morgan JG, Sparks PB.

Heart Rhythm. 2011 May;8(5):643-9. doi: 10.1016/j.hrthm.2011.01.014. Epub 2011 Jan 11.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: reversal of tachycardia-mediated atrial cardiomyopathy with fish oils.

"This suggests that fish oils may target or even reverse underlying cellular and/or structural remodeling that occurs in response to persistent atrial arrhythmias."

Kumar S, Sutherland F, Wheeler M, Heck PM, Lee G, Teh AW, Garg ML, Morgan JG, Sparks PB.

Heart Rhythm. 2011 May;8(5):643-9. doi: 10.1016/j.hrthm.2011.01.014. Epub 2011 Jan 11.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: reversal of tachycardia-mediated atrial cardiomyopathy with fish oils.

"This suggests that fish oils may target or even reverse underlying cellular and/or structural remodeling that occurs in response to persistent atrial arrhythmias."

Kumar S, Sutherland F, Wheeler M, Heck PM, Lee G, Teh AW, Garg ML, Morgan JG, Sparks PB.

Heart Rhythm. 2011 May;8(5):643-9. doi: 10.1016/j.hrthm.2011.01.014. Epub 2011 Jan 11.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: reversal of tachycardia-mediated atrial cardiomyopathy with fish oils.

"This suggests that fish oils may target or even reverse underlying cellular and/or structural remodeling that occurs in response to persistent atrial arrhythmias."

spontaneous echocardiographic contrast

Kumar S, Sutherland F, Wheeler M, Heck PM, Lee G, Teh AW, Garg ML, Morgan JG, Sparks PB.

Heart Rhythm. 2011 May;8(5):643-9. doi: 10.1016/j.hrthm.2011.01.014. Epub 2011 Jan 11.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: reversal of tachycardia-mediated atrial cardiomyopathy with fish oils.

"This suggests that fish oils may target or even reverse underlying cellular and/or structural remodeling that occurs in response to persistent atrial arrhythmias."

Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L.

J Am Coll Cardiol. 2011 Feb 15;57(7):870-9. doi: 10.1016/j.jacc.2010.11.017. Epub 2011 Jan 6.

Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy.

"In patients with NICM and minimal symptoms in response to evidence-based medical therapy, n-3 PUFAs treatment increases LV systolic function and functional capacity and may reduce hospitalizations for HF"

Left ventricular ejection fraction

Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L.

J Am Coll Cardiol. 2011 Feb 15;57(7):870-9. doi: 10.1016/j.jacc.2010.11.017. Epub 2011 Jan 6.

Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy.

"In patients with NICM and minimal symptoms in response to evidence-based medical therapy, n-3 PUFAs treatment increases LV systolic function and functional capacity and may reduce hospitalizations for HF"

Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L.

J Am Coll Cardiol. 2011 Feb 15;57(7):870-9. doi: 10.1016/j.jacc.2010.11.017. Epub 2011 Jan 6.

Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy.

"In patients with NICM and minimal symptoms in response to evidence-based medical therapy, n-3 PUFAs treatment increases LV systolic function and functional capacity and may reduce hospitalizations for HF"

Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L.

J Am Coll Cardiol. 2011 Feb 15;57(7):870-9. doi: 10.1016/j.jacc.2010.11.017. Epub 2011 Jan 6.

Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy.

"In patients with NICM and minimal symptoms in response to evidence-based medical therapy, n-3 PUFAs treatment increases LV systolic function and functional capacity and may reduce hospitalizations for HF"

New York Heart Association functional class

Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, Gheorghiade M, Dei Cas L.

J Am Coll Cardiol. 2011 Feb 15;57(7):870-9. doi: 10.1016/j.jacc.2010.11.017. Epub 2011 Jan 6.

Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy.

"In patients with NICM and minimal symptoms in response to evidence-based medical therapy, n-3 PUFAs treatment increases LV systolic function and functional capacity and may reduce hospitalizations for HF"

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL.

J Nutr. 2011 Feb;141(2):207-13. doi: 10.3945/jn.110.130021. Epub 2010 Dec 22.

Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults.

"DHA supplementation resulted in potentially beneficial changes in some markers of cardiometabolic risk, whereas other markers were unchanged."

Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB.

Heart Rhythm. 2011 Apr;8(4):562-8. doi: 10.1016/j.hrthm.2010.12.017. Epub 2010 Dec 13.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology.

"Chronic fish oil supplementation in humans prolongs atrial refractoriness and reduces vulnerability to inducible AF"

Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB.

Heart Rhythm. 2011 Apr;8(4):562-8. doi: 10.1016/j.hrthm.2010.12.017. Epub 2010 Dec 13.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology.

"Chronic fish oil supplementation in humans prolongs atrial refractoriness and reduces vulnerability to inducible AF"

Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB.

Heart Rhythm. 2011 Apr;8(4):562-8. doi: 10.1016/j.hrthm.2010.12.017. Epub 2010 Dec 13.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology.

"Chronic fish oil supplementation in humans prolongs atrial refractoriness and reduces vulnerability to inducible AF"

Interatrial coronary sinus conduction

Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB.

Heart Rhythm. 2011 Apr;8(4):562-8. doi: 10.1016/j.hrthm.2010.12.017. Epub 2010 Dec 13.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology.

"Chronic fish oil supplementation in humans prolongs atrial refractoriness and reduces vulnerability to inducible AF"

Intra-atrial coronary sinus conduction

Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB.

Heart Rhythm. 2011 Apr;8(4):562-8. doi: 10.1016/j.hrthm.2010.12.017. Epub 2010 Dec 13.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology.

"Chronic fish oil supplementation in humans prolongs atrial refractoriness and reduces vulnerability to inducible AF"

Left atrial coronary sinus conduction

Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB.

Heart Rhythm. 2011 Apr;8(4):562-8. doi: 10.1016/j.hrthm.2010.12.017. Epub 2010 Dec 13.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology.

"Chronic fish oil supplementation in humans prolongs atrial refractoriness and reduces vulnerability to inducible AF"

Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB.

Heart Rhythm. 2011 Apr;8(4):562-8. doi: 10.1016/j.hrthm.2010.12.017. Epub 2010 Dec 13.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology.

"Chronic fish oil supplementation in humans prolongs atrial refractoriness and reduces vulnerability to inducible AF"

Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB.

Heart Rhythm. 2011 Apr;8(4):562-8. doi: 10.1016/j.hrthm.2010.12.017. Epub 2010 Dec 13.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology.

"Chronic fish oil supplementation in humans prolongs atrial refractoriness and reduces vulnerability to inducible AF"

Kumar S, Sutherland F, Rosso R, Teh AW, Lee G, Heck PM, Feldman A, Medi C, Watt S, Garg ML, Sparks PB.

Heart Rhythm. 2011 Apr;8(4):562-8. doi: 10.1016/j.hrthm.2010.12.017. Epub 2010 Dec 13.

Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology.

"Chronic fish oil supplementation in humans prolongs atrial refractoriness and reduces vulnerability to inducible AF"

Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group.

BMJ. 2010 Nov 29;341:c6273. doi: 10.1136/bmj.c6273.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

"This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemic stroke, at least when supplementation is introduced after the acute phase of the initial event."

Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group.

BMJ. 2010 Nov 29;341:c6273. doi: 10.1136/bmj.c6273.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

"This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemic stroke, at least when supplementation is introduced after the acute phase of the initial event."

Myocardial infarction, Non-fatal

Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group.

BMJ. 2010 Nov 29;341:c6273. doi: 10.1136/bmj.c6273.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

"This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemic stroke, at least when supplementation is introduced after the acute phase of the initial event."

Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group.

BMJ. 2010 Nov 29;341:c6273. doi: 10.1136/bmj.c6273.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

"This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemic stroke, at least when supplementation is introduced after the acute phase of the initial event."

Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group.

BMJ. 2010 Nov 29;341:c6273. doi: 10.1136/bmj.c6273.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

"This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemic stroke, at least when supplementation is introduced after the acute phase of the initial event."

Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group.

BMJ. 2010 Nov 29;341:c6273. doi: 10.1136/bmj.c6273.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

"This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemic stroke, at least when supplementation is introduced after the acute phase of the initial event."

Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group.

BMJ. 2010 Nov 29;341:c6273. doi: 10.1136/bmj.c6273.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

"This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemic stroke, at least when supplementation is introduced after the acute phase of the initial event."

Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group.

BMJ. 2010 Nov 29;341:c6273. doi: 10.1136/bmj.c6273.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

"This study does not support the routine use of dietary supplements containing B vitamins or omega 3 fatty acids for prevention of cardiovascular disease in people with a history of ischaemic heart disease or ischaemic stroke, at least when supplementation is introduced after the acute phase of the initial event."

Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM.

JAMA. 2010 Dec 1;304(21):2363-72. doi: 10.1001/jama.2010.1735. Epub 2010 Nov 15.

Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.

8000/4000mg

"Among participants with paroxysmal AF, 24-week treatment with prescription omega-3 compared with placebo did not reduce recurrent AF over 6 months."

Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group.

Circulation. 2010 Nov 23;122(21):2152-9. doi: 10.1161/CIRCULATIONAHA.110.948562. Epub 2010 Nov 8.

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.

"Guideline-adjusted treatment of acute myocardial infarction results in a low rate of sudden cardiac death and other clinical events within 1 year of follow-up, which could not be shown to be further reduced by the application of omega-3 fatty acids."

Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group.

Circulation. 2010 Nov 23;122(21):2152-9. doi: 10.1161/CIRCULATIONAHA.110.948562. Epub 2010 Nov 8.

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.

"Guideline-adjusted treatment of acute myocardial infarction results in a low rate of sudden cardiac death and other clinical events within 1 year of follow-up, which could not be shown to be further reduced by the application of omega-3 fatty acids."

Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group.

Circulation. 2010 Nov 23;122(21):2152-9. doi: 10.1161/CIRCULATIONAHA.110.948562. Epub 2010 Nov 8.

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.

"Guideline-adjusted treatment of acute myocardial infarction results in a low rate of sudden cardiac death and other clinical events within 1 year of follow-up, which could not be shown to be further reduced by the application of omega-3 fatty acids."

Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group.

Circulation. 2010 Nov 23;122(21):2152-9. doi: 10.1161/CIRCULATIONAHA.110.948562. Epub 2010 Nov 8.

OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.

"Guideline-adjusted treatment of acute myocardial infarction results in a low rate of sudden cardiac death and other clinical events within 1 year of follow-up, which could not be shown to be further reduced by the application of omega-3 fatty acids."

Bianconi L, Calò L, Mennuni M, Santini L, Morosetti P, Azzolini P, Barbato G, Biscione F, Romano P, Santini M.

Europace. 2011 Feb;13(2):174-81. doi: 10.1093/europace/euq386. Epub 2010 Nov 8.

n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study.

"Our results do not support the hypothesis that, in patients undergoing ECV of chronic persistent AF, supplementation with PUFAs in addition to the usual antiarrhythmic treatment reduces recurrent AF."

Bianconi L, Calò L, Mennuni M, Santini L, Morosetti P, Azzolini P, Barbato G, Biscione F, Romano P, Santini M.

Europace. 2011 Feb;13(2):174-81. doi: 10.1093/europace/euq386. Epub 2010 Nov 8.

n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study.

"Our results do not support the hypothesis that, in patients undergoing ECV of chronic persistent AF, supplementation with PUFAs in addition to the usual antiarrhythmic treatment reduces recurrent AF."

Bianconi L, Calò L, Mennuni M, Santini L, Morosetti P, Azzolini P, Barbato G, Biscione F, Romano P, Santini M.

Europace. 2011 Feb;13(2):174-81. doi: 10.1093/europace/euq386. Epub 2010 Nov 8.

n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study.

"Our results do not support the hypothesis that, in patients undergoing ECV of chronic persistent AF, supplementation with PUFAs in addition to the usual antiarrhythmic treatment reduces recurrent AF."

Time to atrial fibrillation recurrence

Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni A, Tavazzi L; GISSI-HF investigators.

Eur J Heart Fail. 2010 Dec;12(12):1345-53. doi: 10.1093/eurjhf/hfq172. Epub 2010 Oct 16. Erratum in: Eur J Heart Fail. 2011 Sep;13(9):1042.

Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial.

"n-3 PUFA can provide a small but statistically significant advantage in terms of LV function in patients with symptomatic HF of any aetiology, already treated with recommended therapies."

Left ventricular ejection fraction

Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni A, Tavazzi L; GISSI-HF investigators.

Eur J Heart Fail. 2010 Dec;12(12):1345-53. doi: 10.1093/eurjhf/hfq172. Epub 2010 Oct 16. Erratum in: Eur J Heart Fail. 2011 Sep;13(9):1042.

Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial.

"n-3 PUFA can provide a small but statistically significant advantage in terms of LV function in patients with symptomatic HF of any aetiology, already treated with recommended therapies."

Other echocardiographic parameters

Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group.

N Engl J Med. 2010 Nov 18;363(21):2015-26. doi: 10.1056/NEJMoa1003603. Epub 2010 Aug 28.

n-3 fatty acids and cardiovascular events after myocardial infarction.

"Low-dose supplementation with EPA-DHA or ALA did not significantly reduce the rate of major cardiovascular events among patients who had had a myocardial infarction and who were receiving state-of-the-art antihypertensive, antithrombotic, and lipid-modifying therapy. "

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Hassan KS, Hassan SK, Hijazi EG, Khazim KO.

Ren Fail. 2010;32(9):1031-5. doi: 10.3109/0886022X.2010.510231.

Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients.

"This short-term pilot study demonstrated the efficacy, safety, and well tolerability of omega-3 in the treatment of hypertriglyceridemia in PD patients"

Simão AN, Lozovoy MA, Simão TN, Dichi JB, Matsuo T, Dichi I.

Arq Bras Endocrinol Metabol. 2010 Aug;54(6):540-5.

Nitric oxide enhancement and blood pressure decrease in patients with metabolic syndrome using soy protein or fish oil.

"NO increase and blood pressure reduction with fish oil or soy protein reinforce the importance of the influence of NO on blood pressure in patients with MS."

Serum nitric oxide metabolites

Simão AN, Lozovoy MA, Simão TN, Dichi JB, Matsuo T, Dichi I.

Arq Bras Endocrinol Metabol. 2010 Aug;54(6):540-5.

Nitric oxide enhancement and blood pressure decrease in patients with metabolic syndrome using soy protein or fish oil.

"NO increase and blood pressure reduction with fish oil or soy protein reinforce the importance of the influence of NO on blood pressure in patients with MS."

Simão AN, Lozovoy MA, Simão TN, Dichi JB, Matsuo T, Dichi I.

Arq Bras Endocrinol Metabol. 2010 Aug;54(6):540-5.

Nitric oxide enhancement and blood pressure decrease in patients with metabolic syndrome using soy protein or fish oil.

"NO increase and blood pressure reduction with fish oil or soy protein reinforce the importance of the influence of NO on blood pressure in patients with MS."

Rasmussen LE, Svensson M, Jørgensen KA, Schmidt EB, Christensen JH.

Nutr Res. 2010 Aug;30(8):535-40. doi: 10.1016/j.nutres.2010.07.004.

The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease.

"supplementation with n-3 PUFA does not reduce homocysteine levels in patients with ESRD"

Carney RM, Freedland KE, Stein PK, Steinmeyer BC, Harris WS, Rubin EH, Krone RJ, Rich MW.

Psychosom Med. 2010 Oct;72(8):748-54. doi: 10.1097/PSY.0b013e3181eff148. Epub 2010 Aug 17.

Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease.

"The effects of omega-3 FAs on lnVLF and HR, although modest, were detected after only 10 weeks of treatment with 2 g per day of omega-3"

natural log of very low frequency power (lnVLF)

Carney RM, Freedland KE, Stein PK, Steinmeyer BC, Harris WS, Rubin EH, Krone RJ, Rich MW.

Psychosom Med. 2010 Oct;72(8):748-54. doi: 10.1097/PSY.0b013e3181eff148. Epub 2010 Aug 17.

Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease.

"The effects of omega-3 FAs on lnVLF and HR, although modest, were detected after only 10 weeks of treatment with 2 g per day of omega-3"

Carney RM, Freedland KE, Stein PK, Steinmeyer BC, Harris WS, Rubin EH, Krone RJ, Rich MW.

Psychosom Med. 2010 Oct;72(8):748-54. doi: 10.1097/PSY.0b013e3181eff148. Epub 2010 Aug 17.

Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease.

"The effects of omega-3 FAs on lnVLF and HR, although modest, were detected after only 10 weeks of treatment with 2 g per day of omega-3"

Carney RM, Freedland KE, Stein PK, Steinmeyer BC, Harris WS, Rubin EH, Krone RJ, Rich MW.

Psychosom Med. 2010 Oct;72(8):748-54. doi: 10.1097/PSY.0b013e3181eff148. Epub 2010 Aug 17.

Effect of omega-3 fatty acids on heart rate variability in depressed patients with coronary heart disease.

"The effects of omega-3 FAs on lnVLF and HR, although modest, were detected after only 10 weeks of treatment with 2 g per day of omega-3"

Other Measures of Heart Rate Variability

Haberka M, Mizia-Stec K, Mizia M, Janowska J, Gieszczyk K, Chmiel A, Zahorska-Markiewicz B, GÄ…sior Z.

Clin Nutr. 2011 Feb;30(1):79-85. doi: 10.1016/j.clnu.2010.07.011. Epub 2010 Aug 12.

N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction.

"Early and short-term n-3 PUFA supplementation improved ultrasound indices of endothelial function without affecting serum ADMA levels in patients with AMI and successful primary PCI"

Haberka M, Mizia-Stec K, Mizia M, Janowska J, Gieszczyk K, Chmiel A, Zahorska-Markiewicz B, GÄ…sior Z.

Clin Nutr. 2011 Feb;30(1):79-85. doi: 10.1016/j.clnu.2010.07.011. Epub 2010 Aug 12.

N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction.

"Early and short-term n-3 PUFA supplementation improved ultrasound indices of endothelial function without affecting serum ADMA levels in patients with AMI and successful primary PCI"

Nitroglycerin-mediated dilation

Haberka M, Mizia-Stec K, Mizia M, Janowska J, Gieszczyk K, Chmiel A, Zahorska-Markiewicz B, GÄ…sior Z.

Clin Nutr. 2011 Feb;30(1):79-85. doi: 10.1016/j.clnu.2010.07.011. Epub 2010 Aug 12.

N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction.

"Early and short-term n-3 PUFA supplementation improved ultrasound indices of endothelial function without affecting serum ADMA levels in patients with AMI and successful primary PCI"

asymmetric dimethylarginine (ADMA)

Fahs CA, Yan H, Ranadive S, Rossow LM, Agiovlasitis S, Wilund KR, Fernhall B.

Appl Physiol Nutr Metab. 2010 Jun;35(3):294-302. doi: 10.1139/H10-020.

The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal.

"Commercially available fish-oil supplements taken with an HFM appear to preserve endothelial function following an HFM"

Flow mediated dilation, brachial artery

Fahs CA, Yan H, Ranadive S, Rossow LM, Agiovlasitis S, Wilund KR, Fernhall B.

Appl Physiol Nutr Metab. 2010 Jun;35(3):294-302. doi: 10.1139/H10-020.

The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal.

"Commercially available fish-oil supplements taken with an HFM appear to preserve endothelial function following an HFM"

Fahs CA, Yan H, Ranadive S, Rossow LM, Agiovlasitis S, Wilund KR, Fernhall B.

Appl Physiol Nutr Metab. 2010 Jun;35(3):294-302. doi: 10.1139/H10-020.

The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal.

"Commercially available fish-oil supplements taken with an HFM appear to preserve endothelial function following an HFM"

Fahs CA, Yan H, Ranadive S, Rossow LM, Agiovlasitis S, Wilund KR, Fernhall B.

Appl Physiol Nutr Metab. 2010 Jun;35(3):294-302. doi: 10.1139/H10-020.

The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal.

"Commercially available fish-oil supplements taken with an HFM appear to preserve endothelial function following an HFM"

Fahs CA, Yan H, Ranadive S, Rossow LM, Agiovlasitis S, Wilund KR, Fernhall B.

Appl Physiol Nutr Metab. 2010 Jun;35(3):294-302. doi: 10.1139/H10-020.

The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal.

"Commercially available fish-oil supplements taken with an HFM appear to preserve endothelial function following an HFM"

Fahs CA, Yan H, Ranadive S, Rossow LM, Agiovlasitis S, Wilund KR, Fernhall B.

Appl Physiol Nutr Metab. 2010 Jun;35(3):294-302. doi: 10.1139/H10-020.

The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal.

"Commercially available fish-oil supplements taken with an HFM appear to preserve endothelial function following an HFM"

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Other carotid plaque histological morphology characteristics

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC.

Atherosclerosis. 2010 Sep;212(1):252-9. doi: 10.1016/j.atherosclerosis.2010.05.022. Epub 2010 May 20.

Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.

"Atherosclerotic plaques readily incorporate EPA. A higher plaque EPA content is associated with a reduced number of foam cells and T cells, less inflammation and increased stability."

Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators.

Circ J. 2010 Jul;74(7):1451-7. Epub 2010 May 18.

Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease.

"Subanalysis of the JELIS trial demonstrated that in patients with PAD the incidence of CAD was higher than in controls, and that EPA markedly reduced the occurrence of CAD in those patients."

Gajos G, Rostoff P, Undas A, Piwowarska W.

J Am Coll Cardiol. 2010 Apr 20;55(16):1671-8. doi: 10.1016/j.jacc.2009.11.080.

Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.

"The addition of omega-3 ethyl esters to the combination of aspirin and clopidogrel significantly potentiates platelet response to clopidogrel after percutaneous coronary intervention."

Gajos G, Rostoff P, Undas A, Piwowarska W.

J Am Coll Cardiol. 2010 Apr 20;55(16):1671-8. doi: 10.1016/j.jacc.2009.11.080.

Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.

"The addition of omega-3 ethyl esters to the combination of aspirin and clopidogrel significantly potentiates platelet response to clopidogrel after percutaneous coronary intervention."

Gajos G, Rostoff P, Undas A, Piwowarska W.

J Am Coll Cardiol. 2010 Apr 20;55(16):1671-8. doi: 10.1016/j.jacc.2009.11.080.

Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.

"The addition of omega-3 ethyl esters to the combination of aspirin and clopidogrel significantly potentiates platelet response to clopidogrel after percutaneous coronary intervention."

Platelet aggregation, AA-Stimulated

Einvik G, Klemsdal TO, Sandvik L, Hjerkinn EM.

Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):588-92. doi: 10.1097/HJR.0b013e328339cc70.

A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and Mortality, All-Cause in elderly men at high cardiovascular risk.

"We observed a tendency toward reduction in Mortality, All-Cause in the n-3 PUFA groups that, despite a low number of participants, reached borderline statistical significance."

Einvik G, Klemsdal TO, Sandvik L, Hjerkinn EM.

Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):588-92. doi: 10.1097/HJR.0b013e328339cc70.

A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and Mortality, All-Cause in elderly men at high cardiovascular risk.

"We observed a tendency toward reduction in Mortality, All-Cause in the n-3 PUFA groups that, despite a low number of participants, reached borderline statistical significance."

Madsen T, Christensen JH, Thøgersen AM, Schmidt EB, Toft E.

Europace. 2010 Jul;12(7):941-6. doi: 10.1093/europace/euq085. Epub 2010 Mar 31.

Intravenous infusion of n-3 polyunsaturated fatty acids and inducibility of ventricular tachycardia in patients with implantable cardioverter defibrillator.

"Intravenous n-3 PUFA tended to decrease VT inducibility"

Dawczynski C, Martin L, Wagner A, Jahreis G.

Clin Nutr. 2010 Oct;29(5):592-9. doi: 10.1016/j.clnu.2010.02.008. Epub 2010 Mar 20.

n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study.

"The consumption of n-3 LC-PUFA-supplemented dairy products decreases cardiovascular risk factors."

Dawczynski C, Martin L, Wagner A, Jahreis G.

Clin Nutr. 2010 Oct;29(5):592-9. doi: 10.1016/j.clnu.2010.02.008. Epub 2010 Mar 20.

n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study.

"The consumption of n-3 LC-PUFA-supplemented dairy products decreases cardiovascular risk factors."

Dawczynski C, Martin L, Wagner A, Jahreis G.

Clin Nutr. 2010 Oct;29(5):592-9. doi: 10.1016/j.clnu.2010.02.008. Epub 2010 Mar 20.

n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study.

"The consumption of n-3 LC-PUFA-supplemented dairy products decreases cardiovascular risk factors."

Dawczynski C, Martin L, Wagner A, Jahreis G.

Clin Nutr. 2010 Oct;29(5):592-9. doi: 10.1016/j.clnu.2010.02.008. Epub 2010 Mar 20.

n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study.

"The consumption of n-3 LC-PUFA-supplemented dairy products decreases cardiovascular risk factors."

Dawczynski C, Martin L, Wagner A, Jahreis G.

Clin Nutr. 2010 Oct;29(5):592-9. doi: 10.1016/j.clnu.2010.02.008. Epub 2010 Mar 20.

n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study.

"The consumption of n-3 LC-PUFA-supplemented dairy products decreases cardiovascular risk factors."

Dawczynski C, Martin L, Wagner A, Jahreis G.

Clin Nutr. 2010 Oct;29(5):592-9. doi: 10.1016/j.clnu.2010.02.008. Epub 2010 Mar 20.

n-3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: a double-blind, cross-over study.

"The consumption of n-3 LC-PUFA-supplemented dairy products decreases cardiovascular risk factors."

7,8-dihydro-8-oxo-2'-deoxyguanosine

Eschen O, Christensen JH, LA Rovere MT, Romano P, Sala P, Schmidt EB.

Cell Mol Biol (Noisy-le-grand). 2010 Feb 25;56(1):45-51.

Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure.

"n-3 PUFA may reduce sP-selectin, indicating a possible effect on platelet (and endothelial) activation."

soluble intercellular adhesion molecule-1 (sICAM-1)

Eschen O, Christensen JH, LA Rovere MT, Romano P, Sala P, Schmidt EB.

Cell Mol Biol (Noisy-le-grand). 2010 Feb 25;56(1):45-51.

Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure.

"n-3 PUFA may reduce sP-selectin, indicating a possible effect on platelet (and endothelial) activation."

Soluble Vascular Adhesion Molecule-1 (sVCAM-1)

Eschen O, Christensen JH, LA Rovere MT, Romano P, Sala P, Schmidt EB.

Cell Mol Biol (Noisy-le-grand). 2010 Feb 25;56(1):45-51.

Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure.

"n-3 PUFA may reduce sP-selectin, indicating a possible effect on platelet (and endothelial) activation."

Eschen O, Christensen JH, LA Rovere MT, Romano P, Sala P, Schmidt EB.

Cell Mol Biol (Noisy-le-grand). 2010 Feb 25;56(1):45-51.

Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure.

"n-3 PUFA may reduce sP-selectin, indicating a possible effect on platelet (and endothelial) activation."

Zhao YT, Shao L, Teng LL, Hu B, Luo Y, Yu X, Zhang DF, Zhang H.

J Int Med Res. 2009 Nov-Dec;37(6):1831-41.

Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure.

"n-3 PUFA can reduce levels of plasma inflammatory markers and NT-proBNP as biomarkers of risk stratification in patients with heart failure"

Zhao YT, Shao L, Teng LL, Hu B, Luo Y, Yu X, Zhang DF, Zhang H.

J Int Med Res. 2009 Nov-Dec;37(6):1831-41.

Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure.

"n-3 PUFA can reduce levels of plasma inflammatory markers and NT-proBNP as biomarkers of risk stratification in patients with heart failure"

Zhao YT, Shao L, Teng LL, Hu B, Luo Y, Yu X, Zhang DF, Zhang H.

J Int Med Res. 2009 Nov-Dec;37(6):1831-41.

Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure.

"n-3 PUFA can reduce levels of plasma inflammatory markers and NT-proBNP as biomarkers of risk stratification in patients with heart failure"

Zhao YT, Shao L, Teng LL, Hu B, Luo Y, Yu X, Zhang DF, Zhang H.

J Int Med Res. 2009 Nov-Dec;37(6):1831-41.

Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure.

"n-3 PUFA can reduce levels of plasma inflammatory markers and NT-proBNP as biomarkers of risk stratification in patients with heart failure"

N-terminal pro-brain natriuretic peptide (NT-proBNP)

Zhao YT, Shao L, Teng LL, Hu B, Luo Y, Yu X, Zhang DF, Zhang H.

J Int Med Res. 2009 Nov-Dec;37(6):1831-41.

Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure.

"n-3 PUFA can reduce levels of plasma inflammatory markers and NT-proBNP as biomarkers of risk stratification in patients with heart failure"

Zhao YT, Shao L, Teng LL, Hu B, Luo Y, Yu X, Zhang DF, Zhang H.

J Int Med Res. 2009 Nov-Dec;37(6):1831-41.

Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure.

"n-3 PUFA can reduce levels of plasma inflammatory markers and NT-proBNP as biomarkers of risk stratification in patients with heart failure"

Left ventricular ejection fraction

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF.

Diabet Med. 2010 Jan;27(1):54-60. doi: 10.1111/j.1464-5491.2009.02869.x.

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

"This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM."

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF.

Diabet Med. 2010 Jan;27(1):54-60. doi: 10.1111/j.1464-5491.2009.02869.x.

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

"This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM."

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF.

Diabet Med. 2010 Jan;27(1):54-60. doi: 10.1111/j.1464-5491.2009.02869.x.

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

"This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM."

endothelial progenitor cells (EPCs)

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF.

Diabet Med. 2010 Jan;27(1):54-60. doi: 10.1111/j.1464-5491.2009.02869.x.

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

"This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM."

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF.

Diabet Med. 2010 Jan;27(1):54-60. doi: 10.1111/j.1464-5491.2009.02869.x.

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

"This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM."

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF.

Diabet Med. 2010 Jan;27(1):54-60. doi: 10.1111/j.1464-5491.2009.02869.x.

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

"This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM."

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF.

Diabet Med. 2010 Jan;27(1):54-60. doi: 10.1111/j.1464-5491.2009.02869.x.

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

"This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM."

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF.

Diabet Med. 2010 Jan;27(1):54-60. doi: 10.1111/j.1464-5491.2009.02869.x.

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

"This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM."

glycated haemoglobin (HbA(1c))

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, Tse HF.

Diabet Med. 2010 Jan;27(1):54-60. doi: 10.1111/j.1464-5491.2009.02869.x.

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus.

"This study demonstrated that 12 weeks of fish-oil supplement had no significant beneficial effect on vascular endothelial function, but improved renal function without changes in endothelial function, metabolic profiles, blood pressure, inflammation or oxidative stress in patients with Type 2 DM."

Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, Roller M, Battler A, Kleiman NS, Kornowski R.

J Am Coll Cardiol. 2010 Jan 12;55(2):114-21. doi: 10.1016/j.jacc.2009.08.039.

Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation.

"Treatment of aspirin-resistant patients by adding omega-3 fatty acids or increasing the aspirin dose seems to improve response to aspirin and effectively reduces platelet reactivity."

Platelet aggregation, AA-Stimulated

Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, Roller M, Battler A, Kleiman NS, Kornowski R.

J Am Coll Cardiol. 2010 Jan 12;55(2):114-21. doi: 10.1016/j.jacc.2009.08.039.

Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation.

"Treatment of aspirin-resistant patients by adding omega-3 fatty acids or increasing the aspirin dose seems to improve response to aspirin and effectively reduces platelet reactivity."

Platelet aggregation, ADP-induced

Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, Roller M, Battler A, Kleiman NS, Kornowski R.

J Am Coll Cardiol. 2010 Jan 12;55(2):114-21. doi: 10.1016/j.jacc.2009.08.039.

Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation.

"Treatment of aspirin-resistant patients by adding omega-3 fatty acids or increasing the aspirin dose seems to improve response to aspirin and effectively reduces platelet reactivity."

Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, Roller M, Battler A, Kleiman NS, Kornowski R.

J Am Coll Cardiol. 2010 Jan 12;55(2):114-21. doi: 10.1016/j.jacc.2009.08.039.

Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation.

"Treatment of aspirin-resistant patients by adding omega-3 fatty acids or increasing the aspirin dose seems to improve response to aspirin and effectively reduces platelet reactivity."

Stirban A, Nandrean S, Götting C, Tamler R, Pop A, Negrean M, Gawlowski T, Stratmann B, Tschoepe D.

Am J Clin Nutr. 2010 Mar;91(3):808-13. doi: 10.3945/ajcn.2009.28374. Epub 2010 Jan 13.

Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus.

"n-3 FA supplementation improved postprandial microvascular function."

Stirban A, Nandrean S, Götting C, Tamler R, Pop A, Negrean M, Gawlowski T, Stratmann B, Tschoepe D.

Am J Clin Nutr. 2010 Mar;91(3):808-13. doi: 10.3945/ajcn.2009.28374. Epub 2010 Jan 13.

Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus.

"n-3 FA supplementation improved postprandial microvascular function."

Postprandial flow mediated dilation

Stirban A, Nandrean S, Götting C, Tamler R, Pop A, Negrean M, Gawlowski T, Stratmann B, Tschoepe D.

Am J Clin Nutr. 2010 Mar;91(3):808-13. doi: 10.3945/ajcn.2009.28374. Epub 2010 Jan 13.

Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus.

"n-3 FA supplementation improved postprandial microvascular function."

Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, Gottskalksson G, Palsson R, Indridason OS.

Europace. 2010 Mar;12(3):356-63. doi: 10.1093/europace/eup429. Epub 2010 Jan 7.

Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery?

"There is no evidence for a beneficial effect of treatment with n-3 PUFA on the occurrence of POAF in patients undergoing open heart surgery."

Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC.

Circ Arrhythm Electrophysiol. 2010 Feb;3(1):46-53. doi: 10.1161/CIRCEP.109.899633. Epub 2009 Dec 30.

Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial.

"Omega-3 PUFA do not reduce the risk of AF after coronary artery bypass graft surgery."

Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC.

Circ Arrhythm Electrophysiol. 2010 Feb;3(1):46-53. doi: 10.1161/CIRCEP.109.899633. Epub 2009 Dec 30.

Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial.

"Omega-3 PUFA do not reduce the risk of AF after coronary artery bypass graft surgery."

Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC.

Circ Arrhythm Electrophysiol. 2010 Feb;3(1):46-53. doi: 10.1161/CIRCEP.109.899633. Epub 2009 Dec 30.

Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial.

"Omega-3 PUFA do not reduce the risk of AF after coronary artery bypass graft surgery."

Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC.

Circ Arrhythm Electrophysiol. 2010 Feb;3(1):46-53. doi: 10.1161/CIRCEP.109.899633. Epub 2009 Dec 30.

Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial.

"Omega-3 PUFA do not reduce the risk of AF after coronary artery bypass graft surgery."

Nifontov EM, Shikhaliev DR, Bogachev MI, Krasichkov AS, Shliakhto EV.

Kardiologiia. 2010;50(12):4-9. Russian.

[Antiarrhythmic activity of omega-3 polyunsaturated fatty acids in patients with stable ischemic heart disease and ventricular rhythm disturbances].

"1 g/day omega-3 polyunsaturated fatty acids application in patients with stable CHD without myocardium contraction dysfunction suffering from ventricular arrhythmias (4B grade after B.Lown) with no direct indications for implantable cardioverter defibrillator therapy results in significant reduction of arrhythmia."

Nifontov EM, Shikhaliev DR, Bogachev MI, Krasichkov AS, Shliakhto EV.

Kardiologiia. 2010;50(12):4-9. Russian.

[Antiarrhythmic activity of omega-3 polyunsaturated fatty acids in patients with stable ischemic heart disease and ventricular rhythm disturbances].

"1 g/day omega-3 polyunsaturated fatty acids application in patients with stable CHD without myocardium contraction dysfunction suffering from ventricular arrhythmias (4B grade after B.Lown) with no direct indications for implantable cardioverter defibrillator therapy results in significant reduction of arrhythmia."

Nifontov EM, Shikhaliev DR, Bogachev MI, Krasichkov AS, Shliakhto EV.

Kardiologiia. 2010;50(12):4-9. Russian.

[Antiarrhythmic activity of omega-3 polyunsaturated fatty acids in patients with stable ischemic heart disease and ventricular rhythm disturbances].

"1 g/day omega-3 polyunsaturated fatty acids application in patients with stable CHD without myocardium contraction dysfunction suffering from ventricular arrhythmias (4B grade after B.Lown) with no direct indications for implantable cardioverter defibrillator therapy results in significant reduction of arrhythmia."

Nifontov EM, Shikhaliev DR, Bogachev MI, Krasichkov AS, Shliakhto EV.

Kardiologiia. 2010;50(12):4-9. Russian.

[Antiarrhythmic activity of omega-3 polyunsaturated fatty acids in patients with stable ischemic heart disease and ventricular rhythm disturbances].

"1 g/day omega-3 polyunsaturated fatty acids application in patients with stable CHD without myocardium contraction dysfunction suffering from ventricular arrhythmias (4B grade after B.Lown) with no direct indications for implantable cardioverter defibrillator therapy results in significant reduction of arrhythmia."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Erythrocyte sedimentation rate

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS.

Stroke. 2009 Nov;40(11):3485-92. doi: 10.1161/STROKEAHA.109.555136. Epub 2009 Sep 10.

Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial.

"There was no effect of 12 weeks of treatment with moderate-dose fish oil supplements on cardiovascular biomarkers or mood in patients with ischemic stroke."

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF.

J Hypertens. 2009 Sep;27(9):1863-72.

The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.

"This study has shown that omega3FA reduce blood pressure, heart rate and triglycerides in patients with CKD"

Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A, Vogt PR, Erdogan A.

Thorac Cardiovasc Surg. 2009 Aug;57(5):276-80. doi: 10.1055/s-0029-1185301. Epub 2009 Jul 23.

Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study.

100mg/kg body weight

"Perioperative intravenous infusion of PUFA reduces the incidence of AF after CABG and leads to a shorter stay in the ICU and in hospital."

Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A, Vogt PR, Erdogan A.

Thorac Cardiovasc Surg. 2009 Aug;57(5):276-80. doi: 10.1055/s-0029-1185301. Epub 2009 Jul 23.

Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study.

100mg/kg body weight

"Perioperative intravenous infusion of PUFA reduces the incidence of AF after CABG and leads to a shorter stay in the ICU and in hospital."

Trøseid M, Arnesen H, Hjerkinn EM, Seljeflot I.

Metabolism. 2009 Nov;58(11):1543-9. doi: 10.1016/j.metabol.2009.04.031.

Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men.

"levels of IL-18 were significantly reduced by Mediterranean-like diet and n-3 PUFA supplementation. However, the changes correlated only weakly to changes in triglycerides, serum fatty acids, and anthropometric measures."

Trøseid M, Arnesen H, Hjerkinn EM, Seljeflot I.

Metabolism. 2009 Nov;58(11):1543-9. doi: 10.1016/j.metabol.2009.04.031.

Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men.

"levels of IL-18 were significantly reduced by Mediterranean-like diet and n-3 PUFA supplementation. However, the changes correlated only weakly to changes in triglycerides, serum fatty acids, and anthropometric measures."

Trøseid M, Arnesen H, Hjerkinn EM, Seljeflot I.

Metabolism. 2009 Nov;58(11):1543-9. doi: 10.1016/j.metabol.2009.04.031.

Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men.

"levels of IL-18 were significantly reduced by Mediterranean-like diet and n-3 PUFA supplementation. However, the changes correlated only weakly to changes in triglycerides, serum fatty acids, and anthropometric measures."

Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, Hosseininezhad SJ, Tavallaei S, Vejdani A, Azimi-Nezhad M, Shakeri MT, Rad MA, Mobarra N, Kazemi-Bajestani SM, Ferns GA.

Acta Cardiol. 2009 Jun;64(3):321-7.

Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity.

"It appears that omega 3 improves the cardiovascular risk profile of subjects with metabolic syndrome"

Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, Hosseininezhad SJ, Tavallaei S, Vejdani A, Azimi-Nezhad M, Shakeri MT, Rad MA, Mobarra N, Kazemi-Bajestani SM, Ferns GA.

Acta Cardiol. 2009 Jun;64(3):321-7.

Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity.

"It appears that omega 3 improves the cardiovascular risk profile of subjects with metabolic syndrome"

Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, Hosseininezhad SJ, Tavallaei S, Vejdani A, Azimi-Nezhad M, Shakeri MT, Rad MA, Mobarra N, Kazemi-Bajestani SM, Ferns GA.

Acta Cardiol. 2009 Jun;64(3):321-7.

Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity.

"It appears that omega 3 improves the cardiovascular risk profile of subjects with metabolic syndrome"

Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, Hosseininezhad SJ, Tavallaei S, Vejdani A, Azimi-Nezhad M, Shakeri MT, Rad MA, Mobarra N, Kazemi-Bajestani SM, Ferns GA.

Acta Cardiol. 2009 Jun;64(3):321-7.

Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity.

"It appears that omega 3 improves the cardiovascular risk profile of subjects with metabolic syndrome"

Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, Hosseininezhad SJ, Tavallaei S, Vejdani A, Azimi-Nezhad M, Shakeri MT, Rad MA, Mobarra N, Kazemi-Bajestani SM, Ferns GA.

Acta Cardiol. 2009 Jun;64(3):321-7.

Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity.

"It appears that omega 3 improves the cardiovascular risk profile of subjects with metabolic syndrome"

Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, Hosseininezhad SJ, Tavallaei S, Vejdani A, Azimi-Nezhad M, Shakeri MT, Rad MA, Mobarra N, Kazemi-Bajestani SM, Ferns GA.

Acta Cardiol. 2009 Jun;64(3):321-7.

Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity.

"It appears that omega 3 improves the cardiovascular risk profile of subjects with metabolic syndrome"

Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, Hoseini M, Parizade SM, Farhoudi F, Hosseininezhad SJ, Tavallaei S, Vejdani A, Azimi-Nezhad M, Shakeri MT, Rad MA, Mobarra N, Kazemi-Bajestani SM, Ferns GA.

Acta Cardiol. 2009 Jun;64(3):321-7.

Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity.

"It appears that omega 3 improves the cardiovascular risk profile of subjects with metabolic syndrome"

Bowden RG, Jitomir J, Wilson RL, Gentile M.

J Ren Nutr. 2009 Jul;19(4):259-66. doi: 10.1053/j.jrn.2009.01.030.

Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients.

"The analysis indicates mixed results with respect to cardiovascular disease risk."

Bowden RG, Jitomir J, Wilson RL, Gentile M.

J Ren Nutr. 2009 Jul;19(4):259-66. doi: 10.1053/j.jrn.2009.01.030.

Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients.

"The analysis indicates mixed results with respect to cardiovascular disease risk."

Hartwich J, Malec MM, Partyka L, Pérez-Martinez P, Marin C, López-Miranda J, Tierney AC, Mc Monagle J, Roche HM, Defoort C, Wolkow P, Dembinska-Kieć A.

Clin Nutr. 2009 Oct;28(5):510-5. doi: 10.1016/j.clnu.2009.04.016. Epub 2009 May 28.

The effect of the plasma n-3/n-6 polyunsaturated fatty acid ratio on the dietary LDL phenotype transformation - insights from the LIPGENE study.

"Study demonstrates efficacy of dietary n-3 PUFA to modify pro-atherogenic to less atherogenic LDL phenotype in patients with metabolic syndrome. "

Hartwich J, Malec MM, Partyka L, Pérez-Martinez P, Marin C, López-Miranda J, Tierney AC, Mc Monagle J, Roche HM, Defoort C, Wolkow P, Dembinska-Kieć A.

Clin Nutr. 2009 Oct;28(5):510-5. doi: 10.1016/j.clnu.2009.04.016. Epub 2009 May 28.

The effect of the plasma n-3/n-6 polyunsaturated fatty acid ratio on the dietary LDL phenotype transformation - insights from the LIPGENE study.

"Study demonstrates efficacy of dietary n-3 PUFA to modify pro-atherogenic to less atherogenic LDL phenotype in patients with metabolic syndrome. "

Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan.

Atherosclerosis. 2009 Oct;206(2):535-9. doi: 10.1016/j.atherosclerosis.2009.03.029. Epub 2009 Apr 5.

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

"highly purified EPA is very effective in decreasing the incidence of CAD among Japanese IGM patients, even though the intake of fish is high."

Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators.

Circ J. 2009 Jul;73(7):1283-90. Epub 2009 May 8.

Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.

"EPA is effective for secondary prevention of CAD, especially in individuals with prior MI, and should be added to conventional treatment."

Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y.

J Atheroscler Thromb. 2009 Apr;16(2):83-90. Epub 2009 Apr 30.

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

"These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels."

Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y.

J Atheroscler Thromb. 2009 Apr;16(2):83-90. Epub 2009 Apr 30.

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

"These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels."

Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y.

J Atheroscler Thromb. 2009 Apr;16(2):83-90. Epub 2009 Apr 30.

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

"These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels."

Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y.

J Atheroscler Thromb. 2009 Apr;16(2):83-90. Epub 2009 Apr 30.

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

"These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels."

Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y.

J Atheroscler Thromb. 2009 Apr;16(2):83-90. Epub 2009 Apr 30.

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

"These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels."

Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y.

J Atheroscler Thromb. 2009 Apr;16(2):83-90. Epub 2009 Apr 30.

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

"These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels."

endothelial cell-derived microparticles (EDMP)

Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y.

J Atheroscler Thromb. 2009 Apr;16(2):83-90. Epub 2009 Apr 30.

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

"These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels."

Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y.

J Atheroscler Thromb. 2009 Apr;16(2):83-90. Epub 2009 Apr 30.

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

"These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels."

Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F, Maeda Y.

J Atheroscler Thromb. 2009 Apr;16(2):83-90. Epub 2009 Apr 30.

Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes.

"These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels."

Garbagnati F, Cairella G, De Martino A, Multari M, Scognamiglio U, Venturiero V, Paolucci S.

Cerebrovasc Dis. 2009;27(4):375-83. doi: 10.1159/000207441. Epub 2009 Mar 10.

Is antioxidant and n-3 supplementation able to improve functional status in poststroke patients? Results from the Nutristroke Trial.

"dietary supplementation, even if not able to improve rehabilitation results, is likely to reduce mortality at the 1-year follow-up."

Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G.

Br J Nutr. 2009 May;101(10):1517-26. doi: 10.1017/S0007114508076216. Epub 2009 Feb 27.

Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis.

"The consumption of moderate doses of n-3 LC-PUFA in combination with dairy products did not improve the disease activity. However, there is evidence of cardioprotective effects."

Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G.

Br J Nutr. 2009 May;101(10):1517-26. doi: 10.1017/S0007114508076216. Epub 2009 Feb 27.

Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis.

"The consumption of moderate doses of n-3 LC-PUFA in combination with dairy products did not improve the disease activity. However, there is evidence of cardioprotective effects."

Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G.

Br J Nutr. 2009 May;101(10):1517-26. doi: 10.1017/S0007114508076216. Epub 2009 Feb 27.

Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis.

"The consumption of moderate doses of n-3 LC-PUFA in combination with dairy products did not improve the disease activity. However, there is evidence of cardioprotective effects."

LPS-stimulated COX-2 Expression

Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G.

Br J Nutr. 2009 May;101(10):1517-26. doi: 10.1017/S0007114508076216. Epub 2009 Feb 27.

Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis.

"The consumption of moderate doses of n-3 LC-PUFA in combination with dairy products did not improve the disease activity. However, there is evidence of cardioprotective effects."

Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G.

Br J Nutr. 2009 May;101(10):1517-26. doi: 10.1017/S0007114508076216. Epub 2009 Feb 27.

Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis.

"The consumption of moderate doses of n-3 LC-PUFA in combination with dairy products did not improve the disease activity. However, there is evidence of cardioprotective effects."

Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G.

Br J Nutr. 2009 May;101(10):1517-26. doi: 10.1017/S0007114508076216. Epub 2009 Feb 27.

Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis.

"The consumption of moderate doses of n-3 LC-PUFA in combination with dairy products did not improve the disease activity. However, there is evidence of cardioprotective effects."

8-isoprostaglandin F(2α) (8-iso-PGF(2α)

Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G.

Br J Nutr. 2009 May;101(10):1517-26. doi: 10.1017/S0007114508076216. Epub 2009 Feb 27.

Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis.

"The consumption of moderate doses of n-3 LC-PUFA in combination with dairy products did not improve the disease activity. However, there is evidence of cardioprotective effects."

Dawczynski C, Schubert R, Hein G, Müller A, Eidner T, Vogelsang H, Basu S, Jahreis G.

Br J Nutr. 2009 May;101(10):1517-26. doi: 10.1017/S0007114508076216. Epub 2009 Feb 27.

Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: effects on pathophysiological biomarkers in patients with rheumatoid arthritis.

"The consumption of moderate doses of n-3 LC-PUFA in combination with dairy products did not improve the disease activity. However, there is evidence of cardioprotective effects."

7,8-dihydro-8-oxo-2'-deoxyguanosine

Nomura S, Inami N, Shouzu A, Omoto S, Kimura Y, Takahashi N, Tanaka A, Urase F, Maeda Y, Ohtani H, Iwasaka T.

Platelets. 2009 Feb;20(1):16-22. doi: 10.1080/09537100802409921.

The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients.

"The combination therapy of pitavastatin and EPA may be beneficial for the prevention of vascular complication in hyperlipidemic patients with type II diabetes."

Platelet-derived microparticles (PDMP)

Nomura S, Inami N, Shouzu A, Omoto S, Kimura Y, Takahashi N, Tanaka A, Urase F, Maeda Y, Ohtani H, Iwasaka T.

Platelets. 2009 Feb;20(1):16-22. doi: 10.1080/09537100802409921.

The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients.

"The combination therapy of pitavastatin and EPA may be beneficial for the prevention of vascular complication in hyperlipidemic patients with type II diabetes."

Nomura S, Inami N, Shouzu A, Omoto S, Kimura Y, Takahashi N, Tanaka A, Urase F, Maeda Y, Ohtani H, Iwasaka T.

Platelets. 2009 Feb;20(1):16-22. doi: 10.1080/09537100802409921.

The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients.

"The combination therapy of pitavastatin and EPA may be beneficial for the prevention of vascular complication in hyperlipidemic patients with type II diabetes."

Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-Santos P.

Cardiovasc Diabetol. 2009 Jan 8;8:1. doi: 10.1186/1475-2840-8-1.

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

"Our preliminary findings therefore suggest an additional benefit on postprandial atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin."

Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-Santos P.

Cardiovasc Diabetol. 2009 Jan 8;8:1. doi: 10.1186/1475-2840-8-1.

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

"Our preliminary findings therefore suggest an additional benefit on postprandial atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin."

Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-Santos P.

Cardiovasc Diabetol. 2009 Jan 8;8:1. doi: 10.1186/1475-2840-8-1.

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

"Our preliminary findings therefore suggest an additional benefit on postprandial atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin."

Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-Santos P.

Cardiovasc Diabetol. 2009 Jan 8;8:1. doi: 10.1186/1475-2840-8-1.

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

"Our preliminary findings therefore suggest an additional benefit on postprandial atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin."

Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-Santos P.

Cardiovasc Diabetol. 2009 Jan 8;8:1. doi: 10.1186/1475-2840-8-1.

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

"Our preliminary findings therefore suggest an additional benefit on postprandial atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin."

Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-Santos P.

Cardiovasc Diabetol. 2009 Jan 8;8:1. doi: 10.1186/1475-2840-8-1.

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

"Our preliminary findings therefore suggest an additional benefit on postprandial atherogenic particles when omega 3 fatty acids are added to standard treatment with fluvastatin."

Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA; Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group.

Diabetologia. 2009 Jan;52(1):50-9. doi: 10.1007/s00125-008-1179-5. Epub 2008 Nov 11.

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.

"The impact of omega-3 EE90 on CVD risk will remain uncertain until clinical endpoint trial results are available."

Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA; Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group.

Diabetologia. 2009 Jan;52(1):50-9. doi: 10.1007/s00125-008-1179-5. Epub 2008 Nov 11.

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.

"The impact of omega-3 EE90 on CVD risk will remain uncertain until clinical endpoint trial results are available."

Nodari S, Metra M, Milesi G, Manerba A, Cesana BM, Gheorghiade M, Dei Cas L.

Cardiovasc Drugs Ther. 2009 Feb;23(1):5-15. doi: 10.1007/s10557-008-6142-7. Epub 2008 Nov 4.

The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy.

"N-3 PUFAs administration is associated with favorable effects on parameters related to arrhythmic risk in patients with idiopathic dilated cardiomyopathy."

Nodari S, Metra M, Milesi G, Manerba A, Cesana BM, Gheorghiade M, Dei Cas L.

Cardiovasc Drugs Ther. 2009 Feb;23(1):5-15. doi: 10.1007/s10557-008-6142-7. Epub 2008 Nov 4.

The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy.

"N-3 PUFAs administration is associated with favorable effects on parameters related to arrhythmic risk in patients with idiopathic dilated cardiomyopathy."

Nodari S, Metra M, Milesi G, Manerba A, Cesana BM, Gheorghiade M, Dei Cas L.

Cardiovasc Drugs Ther. 2009 Feb;23(1):5-15. doi: 10.1007/s10557-008-6142-7. Epub 2008 Nov 4.

The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy.

"N-3 PUFAs administration is associated with favorable effects on parameters related to arrhythmic risk in patients with idiopathic dilated cardiomyopathy."

non-sustained ventricular tachycardia (NSVT)